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ABSTRACT OF DISSERTATION 
 
 
ZHX2 REGULATION OF LIPID METABOLISM AND THE BALANCE BETWEEN 
CARDIOVASCULAR AND HEPATIC HEALTH 
The growing obesity epidemic in America carries with it numerous health 
risks, including diabetes, increased serum lipid levels, and excess fat 
accumulation in the liver. If these conditions persist or become exacerbated, they 
may lead to the development of cardiovascular disease, the current leading 
cause of death among Americans, or to nonalcoholic fatty liver disease (NAFLD) 
which can progress to hepatocellular carcinoma (HCC), one of the deadliest 
forms of cancer. Better understanding of the genes involved in these diseases 
can lead to improved identification of at-risk individuals and treatment strategies.   
Our lab previously identified zinc fingers and homeoboxes 2 (Zhx2) as a 
regulator of hepatic gene expression. The BALB/cJ mouse strain has a 
hypomorphic mutation in the Zhx2 gene, causing a 95% reduction in Zhx2 protein 
expression. The near ablation of Zhx2 in BALB/cJ mice confers protection from 
cardiovascular disease when fed a high fat diet, yet these mice show increased 
hepatic lipid accumulation and liver damage. Microarray data indicates Zhx2 may 
be involved in the regulation of numerous genes involved in lipid metabolism. 
Recent GWAS studies indicate ZHX2 may contribute to the risk of cardiovascular 
disease and liver damage in humans as well.  
In this dissertation, I characterize the role of Zhx2 expression in the liver 
and how it affects the risk of both cardiovascular disease and liver damage. I 
generated liver-specific Zhx2 knockout mice and confirmed Zhx2 regulates 
several novel targets that could contribute to the fatty liver phenotype seen in 
BALB/cJ mice. Further studies revealed that hepatic Zhx2 expression is 
necessary for proper sex-specific expression of several Cyptochrome P450 
(CYP) genes and could contribute to gender differences in disease susceptibility. 
Lastly, I performed studies into the functional role of the Zhx2 target gene Elovl3. 
A mouse model of HCC revealed that Elovl3 is completely repressed in HCC 
tumors. Cell viability and cell cycle assays indicate that Elovl3 expression slows 
cell proliferation and may be important for proper cell cycle checkpoints. 
Together, these data indicate that Zhx2 and/or its targets could be clinically 
relevant in the detection, prevention, or treatment of cardiovascular disease, fatty 
liver, and HCC. 
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Chapter One 
Introduction 
The liver is a key metabolic organ in mammals and its proper functioning 
is necessary to maintain health. The liver is responsible for the metabolism of 
macronutrients from dietary intake, including maintaining serum glucose balance, 
synthesizing non-essential amino acids and proteins, regulating lipid utilization 
and storage, and transporting these molecules through the body (Figure 1). 
Additionally, the liver is main site for synthesis of cholesterol and steroid 
hormones, bile acids, and serum transport proteins (i.e. albumin). The diverse 
functions of the liver continue with its role in detoxification of xenobiotic 
compounds and the elimination of harmful or excessive byproducts (ammonia, 
cholesterol) from the body. Most of the described metabolic functions are 
performed by hepatocytes, the predominant cell type in the liver. Hepatocytes 
comprise 80% of the liver mass, but only about 60% of the actual cells within the 
liver. Other liver cell types include Kuppfer cell (resident macrophages) natural 
killer (NK) cells (also known as Pit cells), as well as hepatic stellate cells, which 
serve as Vitamin A stores in quiescent states but produce collagen upon liver 
damage and can lead to fibrosis [1]. The remaining liver cells are sinusoidal and 
biliary endothelial cells which form a cell barrier between hepatocytes and the 
blood and bile ducts, respectively [2]. As hepatocytes are the primary 
contributors to metabolic functions of the liver, they will be the focus of this 
dissertation. 
Liver Lipid Metabolism 
Hepatocytes in the liver are the main site of multiple aspects of lipid 
metabolism and homeostasis. Under fasting conditions, blood glucose levels are 
low which results in the pancreatic release of the peptide hormone glucagon. 
Glucagon binds to receptors expressed on hepatocytes to activate 
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glycogenolysis, the cleavage of glucose molecules from the stored form 
glycogen. If fasting is prolonged and glycogen stores are depleted, glucagon 
activates hormone sensitive lipase in adipose tissue to hydrolyze fatty acids for 
an energy source for most tissues. Fats released from adipose depots undergo 
beta-oxidation in mitochondria to produce two-carbon acetyl-CoA units that are 
substrates for the Citric Acid Cycle and ATP synthesis. Fatty acids can also be 
transported to the liver where they are converted to glucose through 
gluconeogenesis, and during extreme fasting, they are converted to ketone 
bodies as an alternate energy source.  
In the fed state, short chain fatty acids (<C12), carbohydrates, and 
proteins are transported from the small intestine directly to the liver through the 
hepatic portal vein. Longer chain fatty acids, dietary cholesterol, and the fat 
soluble vitamins A, D, E, and K are packaged into triglyceride-rich chylomicrons 
that are transported through circulating blood to peripheral tissues. Interaction 
between apoCII in the chylomicron membrane and the cell surface enzyme 
lipoprotein lipase (Lpl) in peripheral tissues activates Lpl to hydrolyze dietary 
triglycerides into monoglycerol and two free fatty acids that can be transported 
into the cell. Chylomicron remnants or chylomicrons not utilized by peripheral 
tissues are transported through systemic circulation to the liver, where apoE 
binds hepatic receptors to deliver cholesterol, fat-soluble vitamins, and fatty acids 
for processing by hepatocytes. When dietary intake of carbohydrates and/or 
lipids is in excess of immediate physiologic need, hepatocytes convert them to 
triglycerides to be stored mostly in adipose tissue, but also to a lesser degree in 
the liver. Hepatocytes package triglycerides along with cholesterol in VLDL 
particles which are exported into the circulation, and again taken up by peripheral 
tissues by Lpl activation and hydrolysis. After triglycerides are deposited to other 
cells, the remaining cholesterol-containing particles are considered LDL and 
continue to circulate and transport cholesterol to peripheral tissues and back to 
the liver through receptor-mediated endocytosis. Hepatocytes synthesize apoAI 
and apoAII which are incorporated into the membrane of nascent HDL 
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lipoproteins that facilitate cholesterol uptake from peripheral tissues and transport 
it back to the liver, where it may be excreted as bile.  
Hepatocytes respond to increased glucose availability and insulin 
signaling through coordinated transcriptional regulation of genes to increase the 
synthesis of fatty acids and triglycerides. One key event is insulin signaling to 
activate SREBP1c-mediated induction of lipogenesis in the liver, with resulting 
fatty acids and triglycerides then transported in VLDL particles to peripheral 
tissues or adipose for storage [3, 4]. The cellular sterol content regulates the 
activity of SREBP1a and SREBP2 to induce cholesterol biosynthesis [4]. 
Cholesterol is an essential cellular component and is incorporated into 
membranes with roles in signal transduction and transport of molecules. 
Cholesterol is the precursor to bile acids, which are required for the 
emulsification and absorption of lipids in the digestive tract. Cholesterol is also 
the precursor to steroid hormones, including the sex hormones testosterone, 
estrogen and progesterone [5]. Steroid hormone synthesis involves metabolism 
by the cytochrome P450 (CYP) family of enzymes. CYPs function as 
monooxygenases that are involved in both the synthesis and degradation of 
various compounds, including lipid products and steroids, Vitamin D, bilirubin, 
ethanol, drugs, and toxic byproducts from nutrient metabolism [6]. There are a 
large number of CYP enzymes, as each subgroup operates in response to 
specific stimuli. Due to the metabolism of sex hormones and other substances, 
many CYPs are expressed in a gender-specific manner. The regulation of 
sexually dimorphic CYP expression appears to be in response to growth 
hormone signaling [7, 8].  
Disorders of lipid metabolism and health implications 
Disruptions in the synthesis and storage of triglycerides can manifest in a 
variety of detrimental health concerns. A main cause of disregulated lipid 
homeostasis is diet induced obesity, which has quickly risen to epidemic 
proportions in the U.S., with current estimates of 34.9% of adults (78.6 million) 
classifying as obese [9]. The excess energy supply characteristic of obesity is 
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stored as triglycerides in adipose tissue, which can also accumulate in the liver 
[10]. Increased hepatic lipid accumulation has been associated with insulin 
resistance and Type 2 Diabetes, hyperlipidemia, atherosclerosis, 
hepatosteatosis, non-alcoholic fatty liver disease (NAFLD), and hepatocellular 
carcinoma (HCC) [10, 11].  
NAFLD is a term used to describe the excessive presence of lipids in the 
liver that is not a result of alcohol consumption. NAFLD has several categories of 
manifestations with advancing disease states. Hepatic steatosis (fatty liver) is 
characterized as lipid droplet accumulation in hepatocytes and is the result of an 
imbalance in the triglyceride synthesis, transport, or utilization pathways [11]. 
Steatosis is a reversible condition and can be alleviated with dietary and activity 
modifications [12]. Unfortunately, steatosis is highly prevalent in people with 
obesity, type 2 diabetes, and metabolic syndrome, and often progresses to a 
more severe condition, hepatitis [13-15]. Hepatitis is an inflammatory condition 
marked by infiltration of immune cells and increased necrosis and apoptosis of 
damaged cells [15]. It has been strongly implicated that the inflammation 
associated with hepatitis can cause or exacerbate insulin resistance [11, 14, 16]. 
Hepatic inflammation can interfere with normal insulin response and glucose 
utilization, which then results in a metabolic switch to induce lipolysis, releasing 
triglycerides into the blood and causing hyperlipidemia. Dyslipidemia, elevated 
serum glucose, and obesity are key features of metabolic syndrome, which is a 
key risk factor in developing cardiovascular disease [17, 18]. There is growing 
evidence that NAFLD increases atherosclerotic plaque formation and elevates 
incidence of cardiovascular disease [13, 19, 20]. It is difficult to determine if 
NAFLD is an independent cause of atherosclerosis because it usually occurs in 
conjunction with other risk factors. Cardiovascular disease is the leading cause of 
death among Americans, and the number of people at risk is expected to 
continue to increase along with the rising obesity rate [21].  
In addition to the cardiovascular implications of NAFLD, the inflammation 
and increasing damage to hepatocytes can result in fibrosis, the development of 
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scarring that interferes with normal liver function, and cirrhosis. Hepatic stellate 
cells become activated in response to increasing hepatocyte death. Stellate cells 
attempt to repair damaged tissue by expanding collagen fibers and extracellular 
matrix proteins around the injury site [15]. Prolonged damage increases the 
amount of collagen produced and results in cirrhosis. Cirrhosis is considered 
end-stage liver disease and results in liver failure and death [22]. Between 5-30% 
of people with cirrhosis will progress to HCC, depending on the disease severity 
at diagnosis and other risk factors [23]. HCC is the fifth most common cancer and 
is the third leading cause of cancer deaths worldwide. The most common causes 
of HCC are viral infections (hepatitis B and C) and alcohol abuse [15]. Patients 
with these risk factors can undergo serum screening for elevated alpha-
fetoprotein (AFP) and ultrasound imaging for HCC tumor detection, which are 
currently the best methods of identifying HCC. These methods are not highly 
specific or accurate since serum AFP can be elevated in response to any type of 
liver damage, and many people do not present with the traditional risk factors for 
HCC. In recent years, metabolic syndrome and associated NAFLD have become 
increasingly linked to HCC. HCC has a high mortality rate and very poor survival 
prognosis in part because there are few reliable diagnostic markers for HCC, 
which is an alarming realization when paired with a huge potential increase in 
people at risk due to obesity and metabolic syndrome. HCC is projected to be the 
third leading cause of cancer deaths in the United States by 2030 [24]. A better 
understanding of early events in the development of HCC and better detection 
methods is critical to preventing this anticipated surge in HCC related deaths.  
 
Zinc Fingers and Homeoboxes 2 (Zhx2) 
AFP was the first diagnosed oncofetal gene in that it is normally 
expressed during fetal life, silenced at birth, and reactivated in cancer [25]. 
Serum AFP levels is a widely used diagnostic marker to detect liver damage and 
possible HCC, so understanding its expression is of clinical interest. A screen of 
various mouse strains revealed very low AFP levels in adult serum [26]. 
However, the one exception was the BALB/cJ substrain, with serum AFP levels 
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roughly 20-fold higher than other mouse strains (Figure 2). The persistent AFP 
expression in BALB/cJ mice was characterized as a monogenic trait and mapped 
to mouse chromosome 15 [27]. Additional studies indicated that elevated serum 
AFP levels correlated with increased hepatic AFP mRNA levels, suggesting that 
difference was occurring at the level of gene regulation [26].  A molecular screen 
for other genes expressed similarly to AFP (high in fetal liver, silenced at birth, 
persistent expression in adult BALB/cJ liver) identified H19 as another Zhx2 
target [28]. Our lab found that Glypican 3 (Gpc3) is silenced in the perinatal liver 
but expressed at higher levels in BALB/cJ liver [29], similarly to AFP and H19. 
Using positional cloning, our lab identified a mutation in the BALB/cJ Zhx2 allele 
as being responsible for the persistent AFP and H19 expression in the adult liver 
of these mice [30]. For confirmation, overexpression of a liver-specific Zhx2 
transgene in BALB/cJ mice resulted in normal AFP and H19 silencing after birth 
[30] (Figure 3). The mutation in BALB/cJ Zhx2 allele is due to a Mouse 
Endogenous Retroviral (MERV) insertion element within the first Zhx2 intron that 
dramatically reduces, but does not eliminate, Zhx2 expression [30, 31]. Thus, the 
Zhx2 mutation in BALB/cJ mice is hypomorphic, resulting in Zhx2 mRNA levels 
that are roughly 5% of that found in strains with a wild-type Zhx2 allele. These 
combined data suggest that Zhx2 functions to repress target genes in the 
perinatal liver, and the reduction in Zhx2 levels in BALB/cJ livers results in 
persistent expression of these genes.  
Zhx2 is the member of a small family of highly conserved vertebrate-
specific genes (Zhx1, Zhx2 and Zhx3).  Each Zhx protein contains two amino-
terminal C2H2 zinc finger domains, typically associated with DNA, RNA, and 
protein interactions, and four to five carboxy-terminal DNA-binding 
homeodomains, suggesting that these proteins function as transcriptional 
regulators [32]. Early studies indicate that ZHX proteins can homodimerize and 
heterodimerize with each other, and luciferase assays suggest that ZHX proteins 
function as transcriptional repressors [32, 33]. Chromatin immunoprecipitation 
(ChIP) and luciferase reporter assays indicate that ZHX2 binds to and regulates 
the human AFP and Gpc3 promoters [34]. Taken together, these data are 
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consistent with our model of Zhx2 acting to repress AFP and Gpc3 expression in 
the adult liver. Further, ChIP analysis in human HCC cell lines indicate that ZHX2 
binds to the promoter regions of CCNA2 and CCNE1, the genes coding for 
Cyclins A and E, respectively, and inhibited their transcription [35]. However, 
other data suggests Zhx2 may regulate target gene expression at the 
posttranscriptional level (Martha Peterson, unpublished data, [36]). Additionally, 
as described in this dissertation, we have recently identified several novel Zhx2 
targets, including Elovl3, Cyp2a4, and MUPs, that are regulated by Zhx2.  These 
data indicate that Zhx2 is involved in both gene activation and repression.  
Zhx2 targets in HCC and other diseases 
The Zhx2 target AFP serves as a model for examining gene expression in 
fetal development and disease. AFP is expressed at very high levels in the fetal 
liver, repressed over 1000-fold shortly after birth, and becomes reactivated in 
liver damage [25, 37]. AFP is a serum transport protein that circulates lipids, 
steroids, and other substances through the body. Although it is commonly used 
as a diagnostic marker for liver damage and HCC, the functional relevance of its 
increased expression in liver disease is not clear. In humans, hereditary 
persistence of AFP (HPAFP) is considered a benign condition with no known 
health risks [38] Known cases of HPAFP have indicated a mutation in the 
hepatocyte nuclear factor-1 (HNF1) binding site in the AFP promoter results in 
the elevated AFP expression [39, 40]. Although the basis for persistent AFP 
expression in adult BALB/cJ mice is different than HPAFP in humans, they 
similarly do not appear to have any adverse consequences associated with 
increase serum AFP levels.  
Since AFP is frequently reactivated in HCC, there is interest in whether 
other Zhx2 targets and Zhx2 itself are disregulated in HCC. Gpc3 has a similar 
expression pattern to AFP in that it is expressed in the fetal liver, repressed at 
birth, and remains silent in normal adult tissue [41]. Gpc3 is a heparin sulfate 
proteoglycan present on the cell surface and linked to the membrane by 
phosphatidylinositol [42]. Proteins in this category are associated with cell-cell 
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interactions and formation of extracellular matrix, and may integrate signals for 
cell growth and division. Humans with loss of function Gpc3 mutations suffer from 
Simpson-Golabi-Behmel Syndrome (SGBS), characterized by overgrowth in both 
prenatal and postnatal development, multiple body dysmorphisms, and frequent 
death in infancy [43]. Gpc3 knockout mice display many of these maladies, but 
studies in the mice have not elucidated the mechanism that causes SGBS [44]. 
Gpc3 is silenced in normal adult tissues but becomes elevated in HCC, making it 
another candidate HCC diagnostic marker. In fact, some studies suggest Gpc3 is 
more specific for HCC than AFP and could be used for more accurate diagnosis 
[34]. Elevated serum Gpc3 is associated with poor prognosis in HCC patients 
[45] and increased Gpcs3 detected by IHC has over 95% predictive rate of 
pediatric hepatoblastoma [46]. Gpc3 may increase the metastatic properties of 
cells through ERK signaling [47]. Antibodies targeting Gpc3 inhibit Wnt signaling 
and reduce tumor xenografts in nude mice [48], so there is potential for HCC 
therapeutic treatment by regulating Gpc3.  
H19 was the second Zhx2 target to be identified. H19 is a long non-coding 
RNA and serves as a model of parent-of-origin genomic imprinting [49]. The H19 
transcript is processed into microRNA (miR) [50], and may also interact with 
other miRs and thus contributes to gene regulation [51]. H19 knockout mice 
appear to develop normally, yet overexpression of H19 in zygotes results in 
perinatal death [52]. The role of H19 in tumorigenesis has yet to be elucidated. 
Studies have reported increased H19 expression in pancreatic, ovarian, and 
bladder cancers [53-55]. Additional studies suggest that H19 is necessary for 
HCC tumor growth [56], and targeted interference of H19 inhibits cell proliferation 
and induces apoptosis [57]. In contrast, H19 has also been identified as a tumor 
suppressor in colorectal cancer and in HCC [58]. Based on these conflicting data, 
further analysis of the role of H19 in cancer is warranted. In addition to its 
involvement in cancer, polymorphisms in H19 has been associated with 
increased risk of coronary artery disease (CAD) in Chinese men [59]. The impact 
of the polymorphism is unknown, but altered H19 expression increased the risk 
and severity of CAD in the study subjects.  
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Lipoprotein lipase (Lpl) is expressed at high levels in the fetal liver, 
silenced at birth, continues to be expressed at elevated levels in adult BALB/cJ 
liver, and silenced in BALB/cJ mice expressing a liver-specific Zhx2 transgene 
(H. Ren, unpublished). This suggests that Lpl is also a target of Zhx2. Increased 
Lpl expression has been observed in cases of HCC as well as cervical squamous 
cell carcinoma, chronic lymphocytic leukemia, and non-small cell lung cancer 
[60-62]. Lpl facilitates the uptake of fatty acids into cells for energy production, 
which is necessary for the high metabolic requirements of tumorigenic cells [63]. 
Although its expression is altered in cancer, normal Lpl expression is necessary 
for fetal development and cardiovascular health in mature organisms. Lpl 
knockout mice suffer from severe hyperlipidemia and die shortly after birth due to 
blood saturation of chylomicrons and lack of energy in peripheral tissues [64]. 
Partial deletion mutations in human LPL are associated with elevated serum 
lipoproteins [65, 66]. Lpl overexpression in otherwise healthy animal models 
alters lipid metabolism, results in increased atherosclerosis and skeletal muscle 
damage due to lipotoxicity [67, 68], and may contribute to insulin resistance [69]. 
In mouse models of diabetes, increased transgenic Lpl expression has a 
protective effect and has been shown to reduce diabetic hyperlipidemia and 
lessen atherosclerotic lesions [70]. The cardioprotective effect may depend on 
tissue-specific expression, as reduced Lpl in vascular tissue is associated with 
less lipoprotein infiltration [71]. 
 
The disregulation of many Zhx2 targets in HCC leads to question if Zhx2 
expression is also altered in liver cancer. Current data regarding Zhx2 expression 
in HCC tumors are conflicting. A study utilizing sequence screening of tumor and 
adjacent non-tumor tissue reported that CpG islands in the Zhx2 promoter were 
hypermethylated in HCC, resulting in reduced Zhx2 expression in tumors [72]. In 
contrast, another study analyzing tissue samples by immunohistochemistry (IHC) 
noted that Zhx2 protein was expressed only in HCC samples compared to 
cirrhotic liver, cholangitis samples, and normal adjacent tissue [73]. This second 
study also indicated that increased Zhx2 was associated with more advanced 
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stages of HCC. Dr. Chunhong Ma and our collaborators at Shandong University, 
China have found that ZHX2 overexpression reduced proliferation of HCC cells 
as well as reduced the growth of tumor xenografts in nude mice [35]. Further, 
they showed that the Zhx2 proteins were primarily in the nucleus in non-tumor 
liver tissue, but localized to the cytoplasm in HCC samples [35]. This data 
suggests that ZHX2 is excluded from the nucleus in HCC, effectively blocking its 
ability to control expression of target genes. More recently, our collaborators 
published data showing again reduced nuclear ZHX2 localization in HCC tumors 
and a resulting increase in Gpc3 expression in human patient samples [34]. In 
tumor samples from a mouse model of HCC, my analysis indicates increased 
mRNA levels of AFP, Gpc3 and Lpl in tumors compared to control liver samples, 
but no difference in total Zhx2 mRNA expression in normal and HCC samples  
(Figure 4). My analysis of mouse HCC samples indicates that Zhx2 accumulates 
in the cytoplasm and is excluded from the nucleus, consistent with published 
findings. The nuclear exclusion seen in these samples would likely cause the 
disregulation of target genes without necessarily altering the total Zhx2 mRNA or 
protein levels. The mechanism causing the altered Zhx2 localization and 
subsequent disregulation of target gene expression will provide great insight into 
the progression of liver damage and HCC, and may identify new therapeutic 
targets.  
Zhx2 has also been implicated in the regulation of lipid metabolism genes 
and cardiovascular disease risk. Serum lipid analysis performed on various 
mouse strains found that on a high fat diet (HFD), BALB/cJ mice have reduced 
serum lipid levels and fewer atherosclerotic plaques than other strains. 
Quantitative trait locus (QTL) mapping identified this trait, known as 
Hyperlipidemia2 (Hylip2), to a region on mouse chromosome 15 [74]. The Hylip2 
phenotype results in hypertriglyceridemia due to reduced clearance of serum 
triglycerides. The BALB/cJ Hyplip2 allele confers cardiovascular protection by 
increased triglyceride clearance and lower circulating lipid levels, resulting in 
fewer atherosclerotic lesions. In collaboration with the lab of Jake Lusis (UCLA), 
we identified Zhx2 as the gene responsible for the Hylip2 phenotype [75].  
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BALB/cJ mice expressing a liver-specific Zhx2 transgene exhibited significantly 
higher plasma cholesterol and triglycerides and increased atherosclerotic 
plaques compared to non-transgenic BALB/cJ littermates. Consistent with this 
mouse data, ZHX2 has been identified in two human GWAS studies with 
interactions in cardiovascular disease. GWAS analysis of over 31,000 patients in 
the CHARGE consortium identified single nucleotide polymorphisms (SNPs) in 
ZHX2 as the strongest predictive factor of lower carotid intima media thickness 
(cIMT), a subclinical marker of atherosclerosis [76]. A GWAS study analyzing 
data gathered on black and white males in the Bogalusa Heart Study found that a 
particular ZHX2 SNP was strongly associated with cIMT in white males [77]. It is 
not clear how the SNPs evaluated in the study affect the expression or function 
of ZHX2 in humans, but these data indicate ZHX2 has a role in the risk of 
developing cardiovascular disease in humans. The significance of Zhx2 
involvement in serum lipid levels and cardiovascular disease risk is a new 
avenue of investigation for our lab. The Lusis lab performed microarray analysis 
in congenic mice expressing wild-type or the mutated BALB/cJ Zhx2 alleles.  This 
analysis identified over 1000 genes that showed differences in expression in the 
presence or absence of Zhx2 and are therefore potential new targets of Zhx2.  
My dissertation explores the effects of Zhx2 on the regulation of lipid 
metabolism gene expression and resulting disease risk. Many of these studies 
have utilized a novel mouse model I developed that utilized mice with a floxed 
allele of Zhx2 in the BL/6 background; by crossing these mice with Albumin-Cre 
transgenic mice, I have been able to delete Zhx2 specifically in hepatocytes.  I 
have identified several novel Zhx2 targets and further developed the mechanism 
by which hepatic Zhx2 deletion increases hepatic lipid accumulation, resulting in 
lower serum triglycerides and lower risk of cardiovascular disease. I have 
identified the cytochrome P450 enzyme Cyp2a4 as a Zhx2 target, and 
discovered that Zhx2 regulates sexually dimorphic CYP gene expression in the 
adult liver. Additionally, I have characterized the regulation and function of the 
Zhx2 target Elongation of very long chain fatty acids-like 3 (Elovl3) in cell cycle 
regulation and HCC progression.  
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Figure 1. Overview of lipid metabolism in the liver. The liver is the main 
processing site of nutrient metabolites. The liver synthesizes numerous 
Cytochrome P450 (Cyp) enzymes which synthesize cholesterol and bile acids, as 
well as break down drugs, toxins, and other substances to be removed from the 
body. Bile secretion into the intestine is necessary for the absorption of dietary 
fats that are packaged into chylomicron particles. Lipoprotein lipase (Lpl) on the 
surface of peripheral tissues hydrolyzes triglycerides from chylomicrons for 
uptake into cells. Unused remnants travel back to the liver for processing. 
Cholesterol is exported from the liver in VLDL particles for delivery of substances 
to peripheral tissues, and unused particles are reabsorbed by the liver. In cases 
of excess dietary intake, fat can accumulate in the liver, causing non-alcoholic 
fatty liver disease (NAFLD). Continued damage resulting in inflammation and 
macrophage infiltration is characterized as non-alcoholic steatohepatitis (NASH). 
Prolonged damage to the liver increases the risk of hepatocellular carcinoma 
(HCC).  
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Figure 2. Postnatal AFP repression in inbred mouse strains. RNA was 
isolated from mouse livers at embryonic day 19 and periodically from birth to day 
28. Mice have high AFP expression during fetal development which is repressed 
after birth. C3H and B6 mice have rapid and dramatic repression of AFP 
expression.  BALB/cJ mice have delayed onset of repression that is incomplete 
at day 28. BALB/cJ mice continue to express AFP 10 to 20-fold higher than other 
mouse strains. Copyright 1982 Molecular and Cellular Biology.  
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Figure 3. Hepatic Zhx2  transgene expression restores AFP repression. 
Mouse liver RNA amplified by RT-PCR to detect Zhx2, AFP, and Zhx2 transgene 
expression. BALB/c mice with wildtype Zhx2 expression (Lane 1)  have postnatal 
AFP repression. BALB/cJ mice (Lanes 2-3) have greatly diminished Zhx2 
expression and persistent AFP expression. BALB/cJ mice with  liver-specific 
Zhx2 expression (Lanes 4-5) have elevated Zhx2 and restoration of AFP 
repression. These data confirm Zhx2 represses AFP in the mouse liver. L. 
Morford, unpublished data.  
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Figure 4. Zhx2 targets, but not Zhx2, are overexpressed in HCC tumors. 
Male C3H-B6 F1 offspring were injected with PBS (n=5) or DEN (n=16) to initiate 
liver tumor development in a mouse model of HCC. At 36 weeks post-injection, 
liver and tumor samples were collected and analyzed by qPCR for expression of 
Zhx2 (A), and its targets AFP (B), Gpc3 (C), and Lpl (D). AFP, Gpc3, and Lpl 
have increased mRNA expression in HCC tumors, but Zhx2 expression does not 
change. Values are normalized expression shown as fold change to controls.  * 
p<0.05, **p<0.01.  
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Chapter 2  
Materials and Methods 
Mice 
All mice were housed in the University of Kentucky Division of Laboratory Animal 
Research (DLAR) facility and kept according to Institutional Animal Care and Use 
Committee (IACUC) approved protocols. All mice had ad libitum access to food 
and water and were maintained on a 12/12 hour light/dark cycle.  
 
Generation of hepatocyte-specific Zhx2 knockout (Zhx2∆hep) mice:  
Breeding pairs of C57Bl/6 mice with a Zhx2 floxed allele (Zhx2fl) were purchased 
from the Knockout Mouse Project Repository at the University of California-
Davis. In these mice, exon 3 has been flanked by loxP sites. Since the entire 
Zhx2 coding region is found on exon 3, deletion of this exon results in the loss of 
the entire Zhx2 protein.  These mice were crossed with C57/Bl6 mice expressing 
cre recombinase driven by the liver-specific Albumin promoter (Alb-Cre) (Jackson 
Labs). Mice were bred to achieve homozygous floxed Zhx2 alleles with Alb-Cre 
expression (Zhx2∆hep), or without Alb-Cre (Zhx2f/f) serving as littermate controls. 
Mice were maintained under normal conditions until 4-8 weeks old, then 
euthanized by CO2 asphyxiation for tissue harvest.  
 
Genotyping: 
At approximately 10-days of age, each mouse pup was given an ear punch for 
identification and the tissue was collected. DNA was extracted by incubation in 
lysis buffer (100mM Tris-HCl pH 8.5, 5mM EDTA, 200mM NaCl) with 2.5 units 
proteinase K (Sigma) followed by isopropanol precipitation and washing with 
95% ethanol. The DNA pellet was resuspended in water, then genotyped by PCR 
amplification using the appropriate primers (Table 1) with ThermoStart Master 
Mix according to manufacturer’s protocol (ThermoScientific). Samples were 
analyzed by gel electrophoresis and visualized by a UV lightbox. 
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Murine model of atherosclerosis with hepatocyte specific Zhx2 knockout mice:  
A breeding pair of LDLr-/- mice were purchased from Jackson Laboratory. After 
two weeks of acclimation, LDLr-/- mice were bred to Zhx2f/f and Zhx2∆hep mice. 
Offspring were genotyped and crossbred to obtain homozygous LDLr-/- and 
Zhx2f/f with and without Alb-Cre expression. LDLr-/-, Zhx2∆hep and control LDLr-/-, 
Zhx2f/f littermates were weaned onto a high fat, high cholesterol diet (TD.94059, 
Harlan Teklad; Appendix A) at 21 days old and were maintained on this diet for 
18 weeks. Mice were monitored for weight gain every week, and serum 
collections were obtained every 4 weeks throughout the study.  
 
Serum Collection: 
Starting at the second week on the HFD study (mouse age 5 weeks old) and 
repeated every four weeks, serum collections were obtained by submandibular 
bleeding. Mice were fasted starting at 8:00am for five hours but had access to 
water. Mice were manually restrained and punched with a lancet 
(Goldenrod/Medinet) to penetrate the submandibular vein in the cheek. Blood 
was collected in a serum separator tube (~20-100ul blood per collection, 
depending on age of mouse) and incubated at room temperature for at least 30 
minutes before centrifugation at 13000 xg rcf for 1 minute. Serum was aspirated 
by pipetting and transferred to a 1.5ml Eppendorf tube and stored at -80°C.  
 
Euthanasia and Tissue Collection: 
Mice were maintained on HFD for 18 weeks with weekly weight measurements 
and monthly serum collections. After the 18th week, mice were fasted beginning 
at 8:00am for five hours. Mice were weighed and administered Tribromoethanol 
(Avertin) by intraperitoneal injection (250 mg/Kg body weight) and monitored for 
non-responsiveness to sensory stimuli. Mice were dissected and underwent 
transcardial perfusion with PBS to complete exsanguination. For each mouse, 
the liver was removed and separated into three portions: one section was placed 
in OCT media and frozen at -80° (for IHC-F), one section as placed in a tissue 
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cassette and formalin fixed (for IHC-P), and one portion was flash frozen and 
stored at -80° (for RNA extraction). The aorta was removed from surrounding 
tissue and placed with the aortic root perpendicular to the bottom of a tissue 
cassette and fixed in OCT media and frozen at -80°C. 
 
Developmental timepoint studies:  
Female C3H/HeJ (C3H) mice were bred to male C57Bl/6J (Bl/6) mice, and 
female mice were monitored for vaginal plugs to estimate the time of fertilization. 
Pregnant females were euthanized by CO2 asphyxiation at 17.5 days post-
conception and the amniotic sac removed. Neonatal pups were euthanized by 
decapitation, and pups aged more than 14 days were euthanized by CO2 
asphyxiation. All pups were dissected and livers were isolated, frozen, and stored 
at -80° C. 
 
Liver Regeneration:  
Mouse liver regeneration was induced by a single intraperitoneal injection of 
carbon tetrachloride (CCl4). Adult male C3H and Bl/6 mice were administered 
either 0.05 ml mineral oil (MO, n=5) or 0.05 ml 10% CCl4 diluted in MO (n=5). 
After 3 days, animals were euthanized by CO2 asphyxiation, the livers were 
removed, and samples were analyzed by quantitative Real-Time PCR of genes 
indicative of hepatic injury.  
 
Murine model of hepatocellular carcinoma:  
Female C3H mice were bred to male Bl/6 mice and monitored until pups were 
born. At 14 days of age, male offspring were injected with either 
diethylnitrosamine (DEN, n=16) or PBS (n=5) at a dose of 10ul/g body weight. 
Mice were weaned at 21 days of age and maintained under normal conditions for 
36 weeks. Mice were euthanized by CO2 asphyxiation and examined for HCC 
tumor development.  
 
 
18 
 
 
 
RNA extraction, cDNA synthesis, and Quantitative Real-Time PCR: 
Samples were stored at -80° C until needed and then thawed on ice. 
Approximately 100 mg of tissue or 106 cells were homogenized in 1 ml RNAzol 
RT (Sigma #R4533) and mRNA was extracted according to the product technical 
bulletin. Rehydrated RNA was quantified by OD measurement using a NanoDrop 
Spectrophotometer (Thermo Scientific). cDNA was synthesized from 1 ug RNA 
by the iScript cDNA Synthesis Kit (BioRad #170-8891) per manufacturer’s 
protocol. Quantitative Real-Time PCR (qPCR) reactions using SYBR Green PCR 
Supermix (BioRad #172-5275) were performed with a CFX96 Touch Real-Time 
PCR Detection System and results were analyzed with the CFX Manager 
software (BioRad). Oligonucleotide primer sequences are listed in Table 2. qPCR 
Ct values were normalized to the ribosomal protein L30 and is reported as 
Normalized Expression of the indicated gene. Data shown as Fold Change was 
normalized to L30, then values were calculated using the ∆∆Ct method. 
 
Immunohistochemistry: 
Dissected mouse tissues were embedded in OCT media (#), flash frozen, and 
stored at  -80°C. Frozen tissues were acclimated to -20°C and sectioned (10um 
thick) using a Microm HM505 N cryostat. Sections were placed onto glass slides, 
air dried for 10 minutes, then fixed in 4% paraformaldehyde for 10 minutes. 
Slides were washed twice in cold 1xPBS buffer then blocked with the appropriate 
serum blocking buffer at room temperature for one hour. Primary antibody 
detecting Zhx2 (abcam #96083, 1:250) was incubated overnight at 4°C, washed 
twice with 1xPBS, then incubated with secondary antibody (SouthernBiotech 
#4010-13, 1:200)for 1.5 hours at room temperature. Slides were mounted with 
aqueous mounting media (Dako #2013-05) and covered. Slides were imaged 
with a Nikon Eclipse 80i upright microscope with NiS Elements software.  
 
Oil Red O Staining 
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Frozen mouse tissues embedded in OCT were sectioned at 10 um thick using a 
cryostat. Section were fixed in 10% buffered formalin for 10 minutes then washed 
in distilled water for 5 minutes. Slides were submerged in 60% isopropanol for 10 
minutes to dehydrate the tissues. Oil Red O stain (Sigma #O0625, 0.5% in 100% 
isopropanol) was diluted 3:2 in distilled water and filtered. Slides were stained for 
15 minutes while rocking, then washed with 60% isopropanol and counterstained 
with hematoxylin. Slides were mounted and covered and visualized Nikon 
Eclipse 80i upright microscope with NiS Elements software.  
 
Cell Culture: 
Cryopreserved HEK293, Huh7, and HeLa cells were removed from liquid 
nitrogen, thawed, and grown in T25 flasks with Dulbecco’s minimal eagle’s media 
(DMEM, Corning Cellgro #10-017-CV) supplemented with 10% fetal bovine 
serum (FBS, Fisher #03-600-511) and maintained in an incubator at 37°C and 
5% CO2. 
 
Expression Plasmid Cloning:  
A full-length expression vector for mouse Elovl3 was generated by PCR 
amplification (Forward primer: GCCACCATGGACACATCCATGAATTTCTCAC; 
Reverse primer: GGATCCTTGGCTCTTGGATGCAACTTTG) of mouse liver 
cDNA. Amplicons were cloned into the pGEM-T Easy vector (Promega #A1360), 
sequenced, excised using EcoRI and BamHI restriction digests, and cloned into 
the pcDNA3.1 expression vector (Invitrogen V790-20). Elovl3 and empty vector 
pcDNA3.1 expression plasmids were transformed into competent E. coli cells 
using a standard cell transformation protocol. Plasmid preparations were 
performed using a Plasmid Max Kit (Qiagen #12165). DNA was quantified by OD 
measurement using a NanoDrop Spectrophotometer.  
 
Transfection of Expression Plasmids: 
Cells were seeded onto 10 cm2 plates and cultured for 24 hours to obtain 70-
80% confluence. Transfection reactions using Turbofect reagent (Thermo 
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Scientific #R0531) were performed according to the manufacture’s protocol. Cells 
were co-transfected with a GFP expression plasmid to visualize transfection 
efficiency prior to further experimentation.  
 
Growth in Soft Agar:  
Transfected Huh7 cells were cultured for 24 hours, then washed with PBS and 
treated with trypsin to lift cells from the plates. Cell suspensions were centrifuged 
at 1400 x g for 10 minutes at 4°C, decanted, washed with 1 ml PBS and 
centrifuged again, then resuspended in 1 ml PBS. Cells were counted and then 
seeded in 96-well plates with media supplemented agar as described [78]. A 
feeder layer consisting of 25 ul growth media mixed with 25 ul warm 1.2% agar 
(RPI cat #9002-18-0) was added to each well of a 96-well plate and allowed to 
solidify. A cell layer of 25 ul 0.8% agar mixed with 5000 cells suspended in 
growth media was seeded on top of the feeder layer and allowed to solidify. 
Another layer 25 ul growth media with 25 ul 1.2% agar was gently added on top 
of the cell layer. The plate was covered and cultured in the cell incubator for one 
week. Each sample was plated in triplicate wells, and the experiment was 
repeated three times. Cell viability was measured by CellGlo Titer Luminescent 
Cell Viability Assay (Promega #G7570) according to the product protocol and 
results were read on a luminometer. Sample luminescent values were 
normalized to wells containing media and agar layers without cells to account for 
background. Luminescent values for control cells were set to 100% and 
compared to values of Elovl3 transfected cells in three separate experiments.  
 
Cell Synchronization and Analysis of Cell Cycle:  
GFP and Elovl3 or pcDNA3.1 co-transfected cells were cultured for 24 hours 
then synchronized by blocking cell growth using a double Thymidine block. 
Thymidine dissolved in DMEM was added to plates to a final concentration of 2.5 
mM.  After incubation for 17 hours, cells were washed three times with PBS and 
supplied with fresh growth media for 9 hours. At this time, cells were again 
blocked with 2.5 mM Thymidine solution for 15 hours, then washed with PBS. 
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Cells were collected at this time (time 0) and at subsequent hourly timepoints. 
Cells were fixed overnight in 70% ethanol then washed with 1 ml ice cold PBS 
and centrifuged at 1400 x g for 10 minutes at 4°C three times. Cells were 
resuspended in 1 ml cold PBS and treated with RNAse A (Sigma #R-5125) at 
37°C for 30 min. Cells were stained with propidium iodide (Roche 
#11348639001) and strained to remove cell aggregates immediately prior to 
analysis by Flow cytometry. Cells were gated for GFP expression then analyzed 
for DNA content to estimate the number of cell in each phase of the cell cycle. 
Flow cytometry analysis was performed by the Flow Cytometry & Cell Sorting 
core facility at the University of Kentucky.  
 
Statistical analysis: 
All values within a group were averaged and plotted as mean +/- standard 
deviation. p-values were calculated between two groups using student’s t-test 
and between three or more groups by ANOVA followed by Tukey’s test. A p-
value less than or equal to 0.05 was considered significant. Data was graphed 
and analyzed using GraphPad Prism 6 software. 
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Table 1. Primer Sequences, Genotyping.  
 
Gene Sequence (5’) 
Cre Recombinase F: ACCTGAAGATGTTCGCGATTATCT 
R: ACCGTCAGTACGTGAGATATCTT 
LDLr Neo Cassette  F: AGGTGAGATGACAGGAGATC 
R: ACCCCAAGACGTGCTCCCAGGATGA 
R: CGCAGTGCTCCTCATCTGACTTGT 
Zhx2 Floxed Allele  F: GGACCGAATCTCACTATTTAACTCA 
R: ACAACGGGTTCTTCTGTTAGTCC 
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Table 2. Primer Sequences, qRT-PCR 
  
Gene Forward Reverse 
AFP CCGGAAGCCACCGAGGAGGA TGGGACAGAGGCCGGAGCAG 
CD36 AAAGTTGCCATAATTGAGTCCT AAAGTTGCCATAATTGAGTCCT 
ChREBP CATCTCCAGCCTCGTCTTC CTTGGTCTTAGGGTCTTCAGG 
CPT1A ACTCGCTGAAGGTGCTGCTCTC GTGCTGTCATGCGTTGGAAGTC 
CPT1B TTCAACACTACACGCATCCC GCCCTCATAGAGCCAGACC 
CPT2 CACAGCATCGTACCCACCAT TGTCTTCCTGAACTGGC TGTC 
CYP1A1 CCGGCATTCATCCTTCGT GCCATTCAGACTTGTATCTCTTGTG 
CYP1A2 ATCCTTTGTCCCCTTCACCAT GGGAATGTGGGAAGCCATTCA 
CYP2A4 GGAAGACGAACGGTGCTTTC TTC CCA GCA TCA TTC TAA GA 
CYP2A5 GGA AGACGAACG GTG CTT TT TTC CCA GCA TCA TTC GAA GC 
CYP2B9 CCTCGACTACATTGCCCATAG GTTCTGGTGATGGAACTCTGTG 
CYP2B13 GCTTTTCTACCCTTCTCCACAG ATGTCCTTAGAAGCAACAGGGC 
CYP2C40 TGGAAGAGGAAGGATTCCGG TCACTGTGAAGACCCTTGTGG 
CYP2D9 AGAAGTCTCTGGCTTAATTCCTG GTGGTCCTATTCTCAGTCAACAC 
CYP2D10 GAAGGTCTTCCAAGGTCAGAAG CAGCATTCCCCTTTACCTTCTC 
CYP3A16 GATGCCCTCTTTTTGGTTCTGTTGGC TCAGGTTGGAATTCTTCAGGCTCTGG 
CYP3A25 TCCTCTTCACCGAAATCCTGAG TCCTGGGTCCATTTCCAAAGG 
CYP4A10 TCCTTAATGACCCTAGACACTG TGAAAGATATTCCTCACACGGG 
CYP4A12 ATCCTTCTCGATTTGCACCAGG TTCATCGCAAACTGTTTCCCAATG 
CYP7A1 GGGCTGTGCTCTGAAGTTCGG CACAGAGCATCTCCCTGGAGGG 
CYP8B1 CAGAGAAAGCGCTGGACTTC GGCCCCAGTAGGGAGTAGAC 
CYP39A TGGCTCCTGGCGCTGTTTGAG TGGACTGTATTGACGTGTTTCCGTCT 
Elovl1 GTGGCCCAGCCCTACCTTTGG TGGTAGTTGCAGCTGGGCATGA 
Elovl2 TCACCACGCGTCCATGTTCAACA AAGCTGTTCAGGGTGGGTCCAA 
Elovl3 CCTCTGGTCCTTCCTGGCA CGGCGTCATCCGTGTAGATGGC 
Elovl4 GTGGGTGGCTGGAGGCCAAG AGCTGCAGCATGGTCAGGTATCG 
Elovl5 ACTGGGTTCCCTGCGGCCAT TTCCACCAGAGGTAGGGACGCA 
Elovl6 TCCTGTTTTCTGCGCTGTACGCT GCACCAGTTCGAAGAGCACCGA 
Elovl7 TCATGGAGAACCGGAAGCCCTT AACCTGTACCCCAGCCAGACA 
HNF4α GGAAGCTGTCCAAAATGAGCG ATG TCG CCA TTG ATC CCA GAG 
L30 ATGGTGGCCGCAAAGAAGACGAA CCTCAAAGCTGGACAGTTGTTGGCA 
Lpl TGGCTACACCAAGCTGGTGGGA GGTGAACGTTGTCTAGGGGGTAGT 
MAT1a GGCTGAAATTCCTCAAGGAGTCA GGGCAAAGAGGGAGATAGCG 
PPARγ GATTCATGACCAGGGAGTTCCT GGTTGTCTTGGATGTCCTCGAT 
STAT5a CGCTGGACTCCATGCTTCTC GACGTGGGCTCCTTACACTGA 
STAT5b GGACTCCGTCCTTGATACCG TCCATCGTGTCTTCCAGATCG 
SREBP1a CCGAGATGTGCGAACTGGAC GGGAAGTCACTGTCTTGGTTG 
SREBP1c GGAGCCATGGATTGCACATTTG CCTGTCTCACCCCCAGCATA 
SREBP2 GGCGTTCTGGAGACCATG AGGGAAGGAGCTACAAAGTTG 
Zhx2 AGGCCGGCCAAGCCTAGACA TGAGGTGGCCCACAGCCACT 
hCyclin A CTGCATCTCTGGGCGTCTTT GTGCAACCCGTCTCGTCTTC 
hCyclin B TGGTGAATGGACACCAACTCT TAGCATGCTTCGATGTGGCA 
hCyclin D GGATGCTGGAGGTCTGCGA TAGAGGCCACGAACATGCAAGT 
hCyclin E CCCCATCATGCCGAGGGAG TTATTGTCCCAAGGCTGGCT 
hB2M GACTTTGTCACAGCCCAAGATAG TCCATTCCAAATGCGGCATCTTC 
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Chapter 3 
Hepatic Zhx2 regulates lipid metabolism genes that alter risks of fatty liver and 
cardiovascular disease 
 
Introduction 
Obesity in the United States is growing in prevalence, with over one-third 
of adults and almost one-third of children and adolescents classified as obese 
[9]. Obese people face a multitude of adverse health effects, such as 
dyslipidemia, diabetes, hypertension, and Metabolic Syndrome, conditions that 
increase the risk and prevalence of cardiovascular disease (CVD) and non-
alcoholic fatty liver disease (NAFLD). CVD is the leading cause of death of 
Americans with close to 800,000 deaths reported annually, and costing an 
estimated $320 billion in treatment as of 2011 [21]. Obesity and its comorbidities 
have strong associations with high fat diet, physical inactivity, smoking, gender, 
race, and age, yet there are numerous contributing genetic factors that are poorly 
understood.  
 
Obesity-related NAFLD is characterized by excess lipid accumulation in 
the liver, which can lead to inflammation and hepatocyte necrosis and apoptosis, 
classified as non-alcoholic steatohepatitis (NASH). Continuing damage and 
increased fibrosis in the liver can progress to cirrhosis with declining liver 
function. Cirrhosis is a risk factor for the development of hepatocellular 
carcinoma (HCC), which is one of the fastest growing cause of cancer deaths in 
America [24]. It is estimated that roughly 30% of the American population has 
NAFLD, and around 3% of these cases will progress to NASH, then cirrhosis or 
HCC [79]. However, almost 90% of obese people have NAFLD, and alarmingly, 
the mortality rate from HCC is five times higher in obese men than those of 
normal weight [80]. Even without the disease progression to cancer, fatty liver 
presents a significant health threat because it contributes to insulin resistance 
and diabetes which are features of metabolic syndrome and risk factors for CVD. 
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Given the dramatic increase of obese Americans, it is imperative to gain better 
understanding of the metabolic disruptions involved in both CVD and NAFLD.  
Zinc fingers and homeoboxes 2 (Zhx2) is a eukaryotic transcription factor 
identified by the Spear lab as a regulator of gene expression. A natural 
hypomorphic mutation in the BALB/cJ Zhx2 gene is responsible for the Hyplip2 
phenotype in this strain characterized by lower serum triglycerides and fewer 
atherosclerotic plaques when placed on a high fat diet compared to what is seen 
in other mouse strains [74]. BALB/cJ mice expressing a liver-specific Zhx2 
transgene have elevated serum lipid levels similar to other strains, confirming 
that hepatic Zhx2 expression contributes to lipid homeostasis and impacts CVD 
risk [75]. Studies in our lab have shown that BALB/cJ mice exhibit increased lipid 
accumulation and liver damage than other strains on HFD (Clinkenbeard Thesis, 
2011).This is an interesting finding in that BALB/cJ mice develop fatty liver and 
yet are protected from CVD, although the two conditions are usually concordant. 
Understanding Zhx2 regulation and identification of its targets will provide better 
insight into the switch between cardiovascular and hepatic protection seen in 
differing Zhx2 status. Notably, two recent human Genome Wide Association 
Study (GWAS) identified ZHX2 as an important risk factor for carotid intima 
media thickness (cIMT), a subclinical marker of atherosclerosis, although the 
functional role of Zhx2 in these cases was not identified [76, 77].  
Microarray data indicate Zhx2 may regulate numerous genes involved in 
lipid metabolism and transport, including lipoprotein lipase (Lpl), HMG CoA 
synthase, Fatty Acid Synthase (FAS), and CD36, among many others. The 
findings in BALB/cJ transgenic mice suggest that hepatic Zhx2 expression is 
sufficient to reverse the cardio-protective phenotype normally seen in these mice. 
As the liver is the major site of lipid metabolism and coordinates many metabolic 
processes, it is logical to examine the impact of hepatic Zhx2 on lipid metabolism 
genes. However, further exploration of Zhx2 regulation of lipid metabolism in the 
liver is limited by the fact that the mutation in BALB/cJ mice is hypomorphic, not 
null [81]. BALB/cJ mice continue to express low levels of Zhx2, but only around 
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5% of what is seen in other strains of mice. Additionally, Zhx2 is expressed 
ubiquitously and therefore Zhx2 and Zhx2-target genes in other tissues could 
contribute to the Hyplip2 phenotype. To elucidate the role of hepatic Zhx2 
expression on lipid gene regulation, I have developed a hepatocyte-specific Zhx2 
knockout mouse line (Zhx2∆hep). The studies described here analyze the impact 
of Zhx2 deletion from hepatocytes on lipid metabolism and the resulting impact 
on CVD and fatty liver.  
Results 
Confirmation of hepatocyte Zhx2 knockout 
To confirm the establishment of the Zhx2 hepatocyte-specific knockout 
mouse line, male mice were genotyped for the expression of Albumin-Cre. 
Zhx2∆hep and Zhx2f/f control littermates were housed under normal condition until 
6 weeks of age, then euthanized for tissue sample collection. Whole liver RNA 
was analyzed by qPCR for the expression of Zhx2 (Figure 5A). Zhx2∆hep mice 
had 97% decrease in Zhx2 mRNA compared to littermates. The remaining Zhx2 
expression in the RNA sample is likely from other cell types, as Zhx2 remains to 
be expressed in Kupffer cells and other non-parenchymal cells in the liver (B 
Spear, unpublished obs.). Immunofluorescence staining of frozen liver sections 
with antibodies demonstrate Zhx2 proteins localized to the nuclei of hepatocytes 
in Zhx2f/f livers (Figure 5C). In contrast, no Zhx2 staining is observed in 
hepatocytes of Zhx2∆hep mice, although nuclear staining is still evident in non-
parenchymal nuclei (Figure 5D). To confirm further the validity of Zhx2∆hep mice, 
we monitored AFP expression, AFP is known to be repressed by Zhx2 and 
continues to be expressed in synthesized in adult BALB/cJ liver.  RT-qPCR 
indicates that AFP mRNA levels are roughly 10-fold higher in Zhx2∆hep mice 
compared to Zhx2f/f controls (Figure 5B). These results are similar to what is 
observed in BALB/cJ mice, confirming Zhx2∆hep mice provide a valid model to 
study hepatic Zhx2 gene regulation.  
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Zhx2 regulates Cyp2a4, Elovl3, and MAT1a 
The cytochrome P450 member Cyp2a4 is a female-specific enzyme that 
catalyzes the hydroxylation of testosterone [82]. Male BALB/cJ have elevated 
expression of Cyp2a4 [83], so we were interested to investigate a connection 
with Zhx2. Male Zhx2∆hep mice have a 5-fold increase in hepatic Cyp2a4 
expression (Figure 6A). Interestingly, female Zhx2∆hep mice have moderately 
reduced Cyp2a4 compared to wildtype female littermates, indicating Zhx2 has a 
role in the gender-specific hepatic gene expression (Figure 12, Chapter4). This is 
discussed further in Chapter 4.  
A potential Zhx2 target gene is Elongation of very long chain fatty acids-
like 3 (Elovl3). Elovl3 synthesizes mono-unsaturated and saturated fatty acids 
22-24 carbons in length [84]. Elovl3 knockout mice are resistant to diet induced 
obesity, which is attributed to increased fatty acid oxidation to support 
thermogenesis [85, 86]. Elovl3 expression is reduced by more than 50% in 
Zhx2∆hep mice (Figure 6B), making Elovl3 the first identified target of Zhx2 to be 
positively regulated. Elovl3 is further described in Chapter 5. 
Methionine adenosyltransferase Ia (Mat1a) is involved in the synthesis of 
S- adenosylmethionine (SAMe), the sole carbon donor source for DNA 
methylation, which is important for epigenetic gene regulation. Mat1a is not 
detectable in fetal liver, but its expression increases during development and is 
expressed in adult liver. Mat1a is repressed in the regenerating liver and is 
greatly reduced in HCC [87]; other Zhx2 targets are also disregulated in these 
conditions. Under normal treatment, Mat1a knockout mice develop NASH by 6 
months and have spontaneous HCC by 18 months of age [88].  Mat1a mRNA 
levels are reduced in the livers of Zhx2∆hep mice, indicating that the Mat1a gene is 
positively regulated by Zhx2 (Figure 6C).  
Hepatic Zhx2 regulates lipid transport genes Lpl, Cpt1a, and Cd36 
Microarray data from livers of BALB/cJ congenic mice with or without the 
wild-type Zhx2 gene identified numerous genes involved in lipid metabolism and 
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homeostasis as putative Zhx2 targets [75]. We are interested in evaluating these 
target genes that are implicated in the control of lipid metabolism. Lpl was of 
interest due its known role in lipid disorders in humans. Lpl is usually expressed 
on the surface of adipose, skeletal muscle, and other non-hepatic tissues but not 
normally expressed in the adult liver. Lpl is activated by ApoCII to hydrolyze fatty 
acids from chylomicrons and VLDL particles for energy use or triglyceride 
storage within those tissues. qPCR of liver tissue shows that hepatic Lpl 
increases nearly two-fold in the absence of Zhx2 (Figure 7A). Lpl is not highly 
expressed in the liver, so the increase seen in Zhx2∆hep mice could result in fatty 
acid clearance from the serum via increased uptake in the liver. This 
disregulation of hepatic Lpl expression provides a possible mechanism for the 
BALB/cJ Hyplip2 phenotype.  
Studies in our lab have shown that BALB/cJ mice on a HFD have 
significantly increased liver lipid accumulation and liver damage compared to 
BALB/c mice, which have a normal Zhx2 gene (Clinkenbeard Thesis, 2011). This 
suggests that the reduction of Zhx2 results in increased lipid retention in the liver 
and a concomitant reduction in serum lipid levels, leading to CVD resistance. The 
transport of long chain fatty acids across membranes requires the activity of 
various enzymes. The carnitine shuttle consists of three enzymes with 
coordinated processes to move long chain fatty acids across the mitochondrial 
membrane for beta-oxidation [89]. Carnitine palmitoyltransferase-1 (Cpt1) 
replaces the CoA group on long chain fatty acids with carnitine, and the resulting 
acyl-carnitine traverses the outer mitochondrial membrane to the inner 
membrane space. Carnitine translocase shuttles acyl-carnitine through to the 
inner mitochondrial membrane in exchange for a free carnitine recycling back to 
the inner membrane space. The carnitine palmitoyltransferase-2 (Cpt2) enzyme 
then cleaves carnitine and substitutes CoA to yield fatty acyl-CoA, which is a 
substrate for acyl-CoA dehydrogenase in the beta-oxidation pathway. Cpt1a has 
two isoforms: Cpt1a is generally expressed in liver, whereas Cpt1b is expressed 
in muscle. Zhx2∆hep mice have roughly half the wildtype hepatic expression levels 
of Cpt1a (Figure 7C). Cpt1b and Cpt2 expression did not differ between Zhx2∆hep 
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and Zhx2f/f  mice (Figure 7D, 7E). Cpt1a activity is necessary for the proper 
utilization of fats and provides another mechanism to explain the increased liver 
lipid accumulation in BALB/cJ mice.  
CD36, a fatty acid translocase, is another lipid transport enzyme involved 
in the uptake of lipids, including oxidized LDL particles and long chain fatty acids 
[90]. CD36 is expressed in hepatocytes and Kupffer cell in the liver, but is 
typically more abundant in adipocytes, skeletal muscle, endothelial cells, and 
blood cells [91]. CD36 in macrophages facilitates the uptake of long chain fatty 
acids and lipoproteins, notably oxidized LDL particles which initiates foam cell 
formation and atherogenesis [92]. Expression of hepatic CD36 in Zhx2∆hep mice 
is reduced about 45% compared to wildtype mice (Figure 7B).  
Zhx2 interactions with other regulators of lipid metabolism 
Sterol regulatory element binding-proteins (SREBPs) are critical regulators 
of genes that control lipogenesis and therefore of interest as potential 
contributors to the Hyplip2 phenotype. SREBP1a activates LDL receptor 
expression for increased cholesterol uptake into cells and SREBP1c integrates 
insulin signals with lipogenic gene transcription [4]. SREBP2 is a key inducer of 
cholesterol biosynthesis [93]. Mutations in the SREBP genes have been 
associated with NASH and metabolic syndrome [94]. While these functions might 
suggest that SREBP genes could be Zhx2 targets, none of these genes is altered 
in Zhx2∆hep mice (Figure 8A-C). Similar to SREBP1c, the carbohydrate response 
element binding protein (ChREBP) is a regulator of lipid synthesis in the liver, 
though it is activated in response to glucose availability instead of insulin [3, 4] . 
ChREBP expression is reduced roughly 50% in Zhx2∆hep mice (Figure 8D). 
Zhx2 represses transcription factors HNF4α, STAT5a and STAT5b, and PPARγ 
Hepatocyte nuclear factor 4-alpha (HNF4α) is a member of the nuclear 
receptors superfamily and is among the most abundant transcription factor in the 
liver [95]. HNF4α is a key regulator of lipid metabolism, glucose homeostasis, 
and cell differentiation [96, 97] . Because of its importance in the regulation of 
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metabolic genes in the liver, we were interested to see if Zhx2 status had any 
impact on its expression. Indeed, Zhx2 deletion in hepatocytes lowers Hnf4α 
(Figure 9A). Interestingly, liver-specific Hnf4α knockout mice have reduced 
serum cholesterol and triglycerides and increased liver lipid accumulation, as is 
seen in BALB/cJ mice on HFD [96].  
The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear 
receptor known for its role in adipocyte differentiation and increased lipid storage 
capacity [98]. PPARγ is increased in HFD-induced steatosis [99] and adipose 
PPARγ deletion may be protective against HFD insulin resistance [100]. PPARγ 
responds to long chain fatty acids to increase triglyceride synthesis and storage 
[101]. PPARγ is upregulated in the livers of Zhx2∆hep mice (Figure 9B). This could 
contribute to the increased liver damage seen in BALB/cJ on HFD.  
We also investigated the impact of Zhx2 on the transcription factors in the 
Signal Transducer and Activator of Transcription 5 family, STAT5a and STAT5b. 
These factors were identified as essential mediators of growth hormone signaling 
and sex-specific gene expression patterns [7]. The disregulation of Cyp2a4 and 
other CYP genes in male BALB/cJ [93] and Zhx2∆hep mice (Chapter 4) suggested 
a possible interaction with Zhx2. Livers of Zhx2∆hep mice had a modest but 
significant reduction in both STAT5a and STAT5b compared to Zhx2f/f mice 
(Figure 9C, 9D).  
Zhx2∆hep mice on a HFD (preliminary data) 
Analysis of altered hepatic gene expression in Zhx2∆hep mice has provided 
insight into the Hyplip2 phenotype in BALB/cJ mice. Because BALB/cJ mice 
continue to express low levels of Zhx2, one objective of my research is to 
examine the impact of complete hepatocyte Zhx2 deletion on cardiovascular 
disease risk in mice on HFD. To accomplish this, I bred Zhx2∆hep and Zhx2f/f mice 
onto LDLr-/- background. LDLr-/-, Zhx2∆hep and control LDLr-/-, Zhx2f/f littermates 
were weaned onto HFD and maintained on the diet for 18 weeks. This study is 
ongoing, but preliminary data reveals the hepatic consequences of Zhx2 hepatic 
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knockout on HFD. Both cohorts steadily gained weight over the course of the 
study. Although not statistically significant, LDLr-/-, Zhx2∆hep have a slightly 
greater weight increase than controls (Figure 10A). Completion of the study with 
more mice may reveal a difference in weight gain among the groups. H&E 
staining of mice livers shows lipid droplets, hepatocyte ballooning, and distorted 
morphology in both LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f mice (Figure 10B). Oil 
Red O staining indicates LDLr-/-, Zhx2∆hep have dramatically increased lipid 
accumulation compared to LDLr-/-, Zhx2f/f mice, as expected (Figure 10C). 
Further analysis in this study will continue to evaluate the liver phenotype and 
characterize the cardiovascular phenotype, which will include serum lipid 
profiling, aortic root examination for atherosclerotic lesion formation and lipid 
accumulation, and IHC to detect CD68 for macrophage infiltration into cardiac 
tissue.  
Discussion  
BALB/cJ mice, which have a natural hypomorphic mutation in the Zhx2 
gene, have been instrumental in understanding liver gene regulation and lipid 
homeostasis.  Studies described in this chapter demonstrate that the Zhx2∆hep 
mice will also be valuable in understanding the role of Zhx2 in CVD and fatty liver 
disease. Overlapping and sometimes opposing functions of Zhx2-target genes 
identified here make understanding the underlying mechanisms of the Hyplip2 
phenotype complicated. BALB/cJ mice on a HFD have reduced serum 
triglycerides and cholesterol, yet the experience much greater liver lipid 
accumulation and damage (Clinkenbeard Thesis, 2011). Increase in hepatic Lpl 
expression seen in BALB/cJ and Zhx2∆hep mice presumably have increased fatty 
acid uptake into hepatocytes. The decrease in Cpt1a suggests lipids are not 
efficiently metabolized in these mice, which could also contribute to increased 
lipid accumulation. Additionally, when lipids are not utilized for mitochondrial 
beta-oxidation, long chain fatty acids may be shunted to peroxisomes for 
degradation [102]. These pathways produce more damaging oxidative 
byproducts and could contribute to an inflammatory state and increased liver 
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damage in these mice. The impact of decreased CD36 expression in Zhx2∆hep 
mice is not as obvious. CD36 null mice on a HFD have increased serum HDL 
attributed to increased hepatocyte cholesterol and lipoprotein efflux, conferring a 
cardio-protective phenotype in these mice [103]. Another study in CD36 null mice 
showed they were resistant to steatosis on a high carbohydrate and alcohol diet 
[104]. CD36 null mice under LXR activation exhibited less liver lipid accumulation 
than controls [90]. In contrast, CD36 null mice on ob/ob background had reduced 
VLDL secretion and greater steatosis [91]. The VLDL output has not been 
measured in Zhx2∆hep mice, but future investigation could help elucidate the 
impact of diminished CD36. The decrease in Mat1a likely also contributes to the 
NAFLD in BALB/cJ mice. In addition to spontaneous NASH and HCC 
development, Mat1a null mice also have altered plasma lipid levels marked by 
impaired VLDL secretion [87]. The combined impact of these alterations in gene 
expression is the increased clearance of serum triglycerides by elevated hepatic 
Lpl activity, blockage of beta-oxidation and fat usage for energy, and diminished 
secretion of lipids in VLDL. The consequence of these is reduced serum lipids 
and corresponding accumulation of lipids in the liver (Figure 11).  
Data reported in this study suggest cross-talk between Zhx2 and other 
transcription factors that are known regulators of lipid metabolism, adipose 
accumulation, liver injury and inflammation. These results implicate Zhx2 as a 
contributor to these main lipid regulatory networks and hint to a broader role in 
metabolic homeostasis than originally anticipated. The SREBP genes play key 
roles in regulating lipid and cholesterol homeostasis in the liver. The fact that 
they are not altered in Zhx2∆hep mice is curious but not unexpected as we have 
no indications of altered serum glucose levels or insulin sensitivity in these mice. 
We have not directly examined these characteristics but would predict that 
BALB/cJ mice would not exhibit cardiovascular protection on a HFD if they had 
fatty liver as well as altered glucose/insulin responses. 
 Studies in ob/ob mice, as a model of fatty liver and insulin resistance, 
report that ChREBP and SREBP1c synergistically increased after feeding, 
33 
 
 
resulting in increased lipogenesis and eventual steatosis [105]. Knockdown of 
ChREBP in these mice improved insulin sensitivity and lowered hepatic fat 
accumulation and serum triglycerides. Hepatic overexpression of ChREBP in B6 
mice maintained insulin sensitivity when placed on HFD, yet had increased 
steatosis [106]. The basis for decreased expression in ChREBP in Zhx2∆hep mice 
is not clear; analysis of possible changes in serum glucose or insulin response 
may provide insight into the relationship between ChREBP and Zhx2.  
PPARγ is a well characterized transcriptional activator of genes involved 
in adipogenesis and is primarily expressed in adipocytes. An interesting 
relationship exists between PPARγ and Elovl3, in that VLCFAs produced by 
Elovl3 stimulate PPARγ activity, and PPARγ may increase Elovl3 expression 
[107]. Elovl3 expression is ablated in Zhx2∆hep livers, so it would be interesting to 
see if it is upregulated in other tissues to compensate for decreased production in 
the liver. There is some overlap in substrate response with the other elongase 
members, so it is likely that other elongases expressed in the liver are able to 
synthesize the VLCFAs that stimulate PPARγ.  
HNF4α is well established as a master regulator of hepatic gene 
expression and therefore metabolic processes. It is unclear whether HNF4α 
responds directly to fatty acid binding or if it is activated by other mechanisms. 
The similarity in fatty liver and lower serum cholesterol and triglycerides in 
HNF4α liver knockout mice and BALB/cJ mice is consistent with our data that 
Zhx2∆hep mice have reduced HNF4α expression. Further analysis of the 
interaction of  genes regulated by ChREBP, PPARγ, and HNF4α and Zhx2 will 
help explain the relationship between these transcriptional regulators and 
resulting changes in expression of lipogeneic and adipogenic genes. It will be 
interesting to see if Zhx2 directly regulates the expression of these other 
transcription factors and thereby is a master regulator of hepatic gene 
expression.  
To understand the integrated effects of the alterations in these 
transcription factors in the livers of Zhx2∆hep mice, a more thorough metabolic 
34 
 
 
analysis must be completed. Serum panels to assess insulin and glucose repose 
and lipid abundance and content will clarify the role of hepatic Zhx2 in nutrient 
sensing responses and lipoprotein production/export. Zhx2∆hep mice should be 
analyzed for differences in food intake, absorption and excretion, as well as 
alterations in activity level, oxidative capacity, and thermogenesis. Detailed 
analysis of the complete metabolic profile of Zhx2∆hep mice will help identify the 
impact of altered transcription factor expression seen in the mice and understand 
how Zhx2 integrates into established lipid metabolism regulatory networks.  
Since Zhx2 is expressed in many tissues, the role of Zhx2 in other tissues, 
particularly metabolic tissues such as muscle and adipose, will provide further 
insight into Zhx2 and lipid homeostasis.   
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Figure 5. Hepatocyte Zhx2 Knockout Mouse Line. Total liver RNA from Zhx2f/f 
and Zhx2∆hep littermates was analyzed by qPCR for Zhx2 expression (A) and 
AFP (B). Elimination of Zhx2 expression in hepatocytes is confirmed by 
immunofluorescence staining which detected positive nuclear Zhx2 in Zhx2f/f (C) 
compared to Zhx2∆hep (D). *p<0.05, ***p<0.001. 
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Figure 6. Zhx2 regulates hepatic expression of Cyp2a4, Elovl3, and MAT1a. 
Zhx2∆hep mice have increased expression of Cyp2a4 (A), normally expressed at 
very low levels in male mouse liver. Elovl3 is repressed in Zhx2∆hep (B) and is the 
first identified Zhx2 that is positively regulated. MAT1a (C) is repressed in 
Zhx2∆hep. *p<0.05, **p<0.01. 
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Figure 7. Zhx2 regulates lipid transport genes. Zhx2∆hep mice have increased 
expression of Lpl (A), and decreased expression of CD36 (B) and Cpt1a (C). The 
alterations in these genes are consistent with the fatty liver phenotype in 
BALB/cJ mice.  Cpt1b (D) and Cpt2 (E) do not exhibit significant changes in 
Zhx2∆hep liver. *p<0.05, **p<0.01. 
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Figure 8. Zhx2 regulates other regulators of lipid metabolism. Hepatic Zhx2 
expression does not alter the expression of SREBP1a (A), SREBP1c (B), or 
SREBP2(C). The glucose-responsive transcription factor ChREBP is significantly 
reduced in the livers of Zhx2∆hep mice (D). *p<0.05. 
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Figure 9. Zhx2 regulates expression of several hepatic transcription 
factors.  The liver-enriched factor HNF4α is decreased in the absence of Zhx2 
(A), while PPARγ expression is enhanced (B). Signaling effecter genes STAT5a 
(C) and STAT5b (D) are modestly reduced in Zhx2∆hep mice. *p<0.05, **p<0.01.  
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Figure 10. Preliminary data of LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f mice on 
HFD. LDLr-/-, Zhx2∆hep and LDLr-/-, Zhx2f/f littermates were fed HFD for 18 weeks. 
Weight gain is similar in both groups (A). H&E staining of livers shows ballooning 
of hepatocytes and triglyceride accumulation indicative of fatty liver in both 
cohorts (B). Noticeably increased lipid accumulation is detected in LDLr-/-, 
Zhx2∆hep livers by Oil Red O staining (C).  
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Figure 11. Impact of Hepatic Zhx2 Deletion. Zhx2∆hep mice have altered 
expression of numerous genes important for lipid metabolism. Hepatic Lpl 
expression increases triglyceride uptake to the liver. Repression of Cpt1a and 
Elovl3 reduces hepatic capacity to metabolize and export lipids and cholesterol 
from the liver, increasing retention and damage. Lowered Mat1a may 
independently contribute to NAFLD development. Decrease in HNF4α and 
increase in PPARγ expression could alter normal hepatic gene regulation on a 
global scale. The increase accumulation and reduced export of lipid in the liver 
effectively lower serum lipids and reduce atherogenesis.  
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Chapter 4 
Zhx2 regulates sexually dimorphic CYP gene expression in the adult mouse liver 
Introduction 
The cytochrome P450 (CYP) supergene family is one of the largest and 
most diverse gene families in eukaryotes [108, 109]. CYP genes encode 
structurally related enzymes that catalyze a variety of metabolic reactions, 
including metabolism of steroid-based hormones, lipids, drugs and environmental 
chemicals [110]. In humans, mutations in CYP genes contribute to a variety of 
metabolic diseases [111], and polymorphisms in CYP genes are a major 
contributor to variations in susceptibility to xenobiotics [112, 113]. The CYP 
supergene family arose through numerous duplication events. In vertebrates, the 
number of CYP genes and pseudogenes vary dramatically between different 
species. Analysis of genome databases suggests that humans contain 57 
functional CYP genes and 58 pseudogenes, whereas mice contain 102 functional 
CYP genes and 88 pseudogenes.  
CYP genes exhibit a variety of expression patterns. Some CYP genes are 
expressed in numerous tissues, whereas expression of other CYP genes is more 
highly restricted to one or several tissues. The liver has the highest level of CYP 
expression, which is not surprising since ingested xenobiotics enter the liver 
before circulation elsewhere in the body. Numerous drugs and xenobiotics can 
induce CYP gene expression; much of this is governed by members of the 
nuclear receptor family, including the Constitutive Androstane Receptor (CAR), 
aryl hydrocarbon receptor (AhR), pregnane X receptor (PXR), and peroxisome 
proliferator activated receptor α (PPARα) [114].  As with structural 
polymorphisms in CYP enyzmes, variation in the expression and induction of 
CYP enzymes in response to xenobiotics can lead to different responses to these 
agents. These variations must be considered when comparing the metabolism 
and toxicity of drugs and environmental chemicals between different humans as 
well as different species such as mice and humans [115]. 
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One common feature of many vertebrate CYP genes is sexual dimorphic 
expression [116]. Many CYP genes, including Cyp 2d9 and Cyp4a12, are 
expressed primarily in males [117]. In contrast, other CYP genes such as 
Cyp2b9 and 2b13 show a female-biased pattern of expression [117]. The degree 
of sex-biased expression varies considerably. Differences in circulating Growth 
Hormone (GH) levels play an important role in this sexually dimorphic expression 
[118]. In the liver, the transcription factors STAT5a/b and hepatocyte nuclear 
factor 4α (HNF4α) help govern gender-specific expression [8, 119, 120]. 
A dramatic example of sexually dimorphic expression is seen with the 
Cyp2a4 gene in mice. In normal adult liver, the mouse Cyp2a4 gene is 
expressed abundantly in female livers with very low hepatic expression in adult 
males [121]. Curiously, Cyp2a4 expression in adult male BALB/cJ mice is almost 
equal to what is seen in female mice [83] . The high Cyp2a4 mRNA levels 
observed in BALB/cJ males is an autosomal recessive trait. This led to the 
suggestion that the absence of Cyp2a4 expression in male mice is due to a 
transcriptional repressor, and that a mutation resulting in the loss of this putative 
repressor in BALB/cJ mice results in de-repression of Cyp2a4 in adult BALB/cJ 
male liver. 
Several years ago, we identified Zinc fingers and homeoboxes 2 (Zhx2) as 
a regulator of gene expression in the postnatal liver. Several Zhx2 target genes, 
including alpha-fetoprotein (AFP), H19, and Glypican 3 (Gpc3) are expressed 
abundantly in the fetal liver and dramatically repressed in the first several weeks 
after birth [29, 81]. In contrast to most strains of mice, AFP, H19 and Gpc3 
continues to be expressed in the adult liver of BALB/cJ mice. The continued 
expression of these genes in BALB/cJ liver, where adult liver AFP mRNA levels 
are 10- to 20-fold higher than other mouse strains, is an autosomal recessive trait 
regulated by a locus on Chromosome 15. Using positional cloning, we found that 
elevated AFP, H19 and Gpc3 mRNA levels in BALB/cJ livers was due to a 
hypomorphic mutation in the Zhx2 gene that dramatically reduces Zhx2 levels.  
Interestingly, when placed on a high fat diet, BALB/cJ mice have fewer serum 
44 
 
 
triglycerides and reduced atherosclerotic lesions compared to other mouse 
strains on the same diet.  This strain difference is also due to the Zhx2 mutation, 
and several proteins involved in lipid/cholesterol homeostasis are disregulated in 
BALB/cJ livers. Taken together, these data indicate that Zhx2 is an important 
regulator of numerous hepatic genes in the adult liver. 
Zhx2 is a member of a small gene family that also contains Zhx1 and 
Zhx3. The Zhx proteins contain two amino-terminal C2-H2 Zinc fingers and four 
(or five, in the case of Zhx1) carboxy-terminal homeodomains. In vitro studies 
suggest that Zhx proteins function as transcriptional repressors. This, along with 
the fact that the Zhx2 gene is mutated in BALB/cJ mice, led us to investigate 
whether the mutation in Zhx2 could account for elevated Cyp2a4 expression in 
adult male BALB/cJ mice. Using several mouse models, our data indicate that 
Cyp2a4 is a target of Zhx2 repression. In contrast to Cyp2a4, expression of the 
highly related Cyp2a5 gene shows little change in the absence of Zhx2. 
Furthermore, we demonstrate that numerous other sex-biased CYP enzymes 
exhibit altered expression in the absence of Zhx2. In general, female-biased CYP 
enzymes exhibit increased expression in males but male-biased CYP enzymes 
show little change in either sex. Levels of Cyp7a1 mRNA, which is present at 
high levels in both male and female liver, are increased in males and reduced in 
females in the absence of Zhx2. This data indicates that Zhx2 is an important 
regulator of sex-specific expression of CYP enzymes in the liver.   
Results 
Cyp2a4 mRNA levels are higher in the liver of male Zhx2∆hep mice 
Cyp2a4 is normally expressed at high levels in adult liver of female mice but not 
expressed in adult male liver. An exception to this is seen in BALB/cJ mice, in 
which Cyp2a4 mRNA levels are almost equal in both male and female adult liver. 
We asked whether Zhx2, which is mutated in BALB/cJ mice, could account for 
this strain-specific trait. To accomplish this, we analyzed Cyp2a4 expression in 
BL/6 mice with a hepatocyte-specific deletion of Zhx2. Mice with a floxed Zhx2 
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allele (described in Chapter 2) were bred with Albumin-Cre (Alb-Cre) transgenic 
mice to generate mice that were homozygous for the floxed Zhx2 gene and Alb-
Cre+ (Zhx2∆hep); floxed homozygous littermates that did not contain the Alb-Cre 
transgene (Zhx2f/f) were used as controls.  Zhx2 is efficiently silenced in the 
hepatocytes of Zhx2∆hep mice but still expressed in non-parenchymal cells 
(Chapter 3, Figure 5). In control Zhx2f/f mice at 5 weeks of age, Cyp2a4 is 
expressed in females but barely detectable in males as expected. In contrast, 
Cyp2a4 mRNA levels are increased nearly 90-fold in age matched Zhx2∆hep male 
mice to levels that are comparable to those seen in female Zhx2∆hep adult liver, 
which show a ~40% reduction in Cyp2a4 levels compared to Zhx2f/f females 
(Figure 12A, B). These data indicate that Zhx2 is responsible for the low Cyp2a4 
levels in adult male mice. Interestingly, Cyp2a5, which is highly related to 
Cyp2a4, does not exhibit sex-biased expression or significant differences 
between Zhx2∆hep and Zhx2f/f mice. 
Cyp2a4 levels exhibit gender-specific changes in the postnatal liver 
Previously identified Zhx2 targets, including AFP, H19 and Gpc3, are expressed 
abundantly in the fetal liver and silenced after birth. In contrast to Cyp2a4, these 
genes do not exhibit gender-biased expression. This led us to investigate 
Cyp2a4 in the fetal liver and postnatal patterns of Cyp2a4 expression in male 
and female wildtype mice. In both sexes, Cyp2a4 levels are very low in the e17.5 
liver and show a gradual increase during the first four weeks after birth.  A 
modest increase in Zhx2 mRNA levels is also seen at this time (Figure 13A, B). 
However, the gender bias in the liver is evident at p28, with female Cyp2a4 levels 
roughly 8-fold higher than that seen in males (Figure 13C, D). A dramatic change 
in this pattern occurs between four weeks and eight weeks of age. In male mice, 
Zhx2 levels increase roughly 6-fold during this period (Figure 13A), whereas 
Cyp2a4 levels are dramatically reduced to barely detectable levels (Figure 13C). 
In contrast, Zhx2 and Cyp2a4 levels show modest changes in the female liver 
during this time period (Figure 13B, D). This data supports the possibility that 
Zhx2 contributes to Cyp2a4 silencing in the adult male liver, and that full 
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repression is associated with sexual maturity that occurs between 4 and 8 weeks 
of age. 
A number of CYP enzymes in addition to Cyp2a4 exhibit gender-specific 
expression, with some being expressed at higher levels in male and others in 
females.  Since male-specific Cyp2a4 mRNA levels increased in Zhx2∆hep mice, 
we evaluated expression of other hepatic Cyp enzymes in the presence or 
absence of Zhx2. Eight Cyp genes that are normally expressed at higher levels in 
females were examined. In general, the loss of hepatic Zhx2 resulted in 
increased expression in adult male liver (Figure 14). The increase was robust in 
several cases (27-fold and 9-fold for Cyp2b13 and Cyp2b9, respectively) and 
more modest for other enzymes (2- to 3-fold for Cyp4a10, Cyp2c40, Cyp 3a16 
and Cyp39a). Zhx2 did not affect expression of Cyp1a1 or Cyp1a2 in males. 
Expression of these genes was the same or slightly less in females Zhx2∆hep 
mice than in Zhx2f/f only  This pattern is similar to what was seen with Cyp2a4 
(Figure 12). A different pattern was seen with several male-biased Cyp enzymes. 
In two that were analyzed, Cyp2d9 and Cyp8b1, showed little change in either 
sex in Zhx2∆hep liver compared to Zhx2f/f liver (Figure 15). Cyp4a12 was 
repressed in female Zhx2∆hep mice. Three Cyp enzymes that are expressed 
equally in both sexes were examined (Figure 16). Cyp3a25 and Cyp2d10 did not 
respond to the loss of Zhx2 whereas Cyp7a1 was slightly increased in males and 
decreased in females. Interestingly, Cyp7a1 codes for the rate-limiting enzyme 
that converts cholesterol to bile acids so alterations in its expression likely affects 
cholesterol metabolism.  
Cyp2a4 mRNA levels are increased in HCC 
Previously identified genes that are repressed by Zhx2, including AFP, 
H19 and Gpc3, are silent in the healthy adult liver but frequently reactivated in 
HCC.  Since Cyp2a4 also appears to be negatively regulated by Zhx2, we asked 
whether it was also disregulated in HCC.  Analysis of RNA from normal C3B6F1 
male mouse liver and male HCC tumors induced by DEN (described in Chapter 
2) indicated that Cp2a4 levels were significantly increased in tumors (Figure 17).  
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Discussion 
Data in this chapter provide the first evidence that Zhx2 contributes to 
gender-biased gene expression in the adult liver. The sexually dimorphic 
expression of CYP genes is well documented, but the involvement of Zhx2 
regulation of genes in a sex-specific manner provides a link between 
developmental gene regulation and gender-biased expression. Zhx2 represses 
targets AFP, H19, and Gpc3 in normal adult mouse liver, and these genes have 
similar expression levels in males and females. Zhx2 positively regulates Elovl3 
in mouse liver during development (discussed in Chapter 5). After sexual 
maturity, Elovl3 is more abundant in male liver, and is expressed in a circadian 
rhythm only in male liver [122]. Data presented here shows that Zhx2 positively 
regulates Cyp2a4 in male and female liver during development, but between 4-8 
weeks of age, Zhx2 is required for full Cyp2a4 repression in male liver.    
Cyp2a4 and other Cyp enzymes, along with Elovl3, exhibit circadian 
patterns of expression. Cyp2a4 circadian regulation in male mice is attributed to 
integration of growth hormone (GH) signaling via STAT5 activation [8, 123]. 
STAT5b expression is necessary for expression of male-specific Cyp genes, 
whereas both STAT5a and STAT5b expression are required for female gene 
patterning [119]. The expression of the appropriate STAT5 isoforms coordinates 
the expression of genes in a sex-specific manner in response to GH signaling. 
GH is expressed in a pulsating manner in males while females have more steady 
GH circulation [120]. HNF4α is a key regulator of gene expression in the liver. 
Almost half of actively transcribed hepatic genes containing response elements 
[95], suggesting that HNF4α affects more target genes than other hepatic 
transcription factors. Studies in HNF4α-deficient mice showed this factor to be 
necessary for the expression of several sex-specific Cyps [124]. A current model 
of integration of HNF4α with GH signaling suggests the pulsating spike in GH in 
male mice activates STAT5b, and possibly HNF4a, which translocate to the 
nucleus and increase transcription of male specific Cyp genes (Figure 18). 
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Increased HNF4a suppresses HNF6 and HNF3β which are associated with 
expression of female Cyps. The continuous GH levels in females correspond with 
increased HNF6 and HNF3β activity and fail to activate STAT5b and therefore 
fail to activate male Cyp expression [124, 125]. These combined studies indicate 
that GH pulses and activation of STAT5b and HNF4α are critical to male Cyp 
expression. Interestingly, qPCR data in Zhx2∆hep mice suggest hepatic Zhx2 
deletion reduces the expression of HNF4α, STAT5a, and STAT5b (Chapter 3). 
As each of these transcription factors is a critical component of sex-specific gene 
regulation, the reduction in Zhx2∆hep mice could help explain the disregulation of 
multiple Cyp genes in the livers of both male and female Zhx2∆hep mice. Further 
examination into the potential interaction of Zhx2 with HNF4α and STAT5 is 
warranted by these findings, and could elucidate the mechanism by which sex-
biased genes are regulated in the liver.   
We provide evidence that Cyp2a4 is activated in HCC, similarly to other Zhx2 
targets. Disregulated expression of various CYP genes has been associated with 
human liver disease risk. Data from human tissue arrays of HCV infected, HCV 
infected with HCC, and non-HCV normal livers identified differential expression of 
27 different CYPs depending on disease state and severity [126]. The pattern of 
expression varies; CYP2C9 is lower in HCC cases with larger tumors, whereas 
CYP51A1 increases with tumor size. CYP2B6, CYP2C9, CYP2C19, CYP3A5, 
CYP4F3, CYP27A1, CYP2E1, and CYP4F2 were lower in HCC with greater 
vascularization and thus more advanced progression [126]. A qRT-PCR panel of 
numerous CYPs revealed that HCC tissues generally have lower CYP 
expression than non-tumor tissue; however, HCC samples that overexpress one 
CYP gene usually exhibit higher expression of several CYPs [127]. Diminished 
CYP2E1 has been associated with increased tumor aggression and poor 
prognosis in HCC patients [128]. These studies confirm that CYP expression is 
often disregulated in HCC and the degree of disregulation could correlate with 
the advancement of disease. Data from our collaborator [35] indicates that 
nuclear Zhx2 levels are reduced in HCC samples compared to non-tumor liver 
tissue, suggesting that this differential localization of Zhx2 could account for the 
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lack of repression of Zhx2 targets in HCC. Additional studies will be needed to 
further explore whether reactivation of CYP enzymes in cancer is due, at least in 
part, to changes in Zhx2.   
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Figure 12. Zhx2 regulates Cyp2a4 in a gender-specific manner. Adult male 
Zhx2∆hep mice have 90-fold increase in Cyp2a4 expression (A), whereas female 
Zhx2∆hep have about 40% reduced expression (B) when compared to Zhx2f/f 
controls. This data suggests Zhx2 positively regulates Cyp2a4 in female mouse 
liver and represses it in adult male liver. *p<0.05.  
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Figure 13. Zhx2 regulation of Cyp2a4 during development. Liver RNA 
extracted from C3B6F1 offspring at development timepoints was analyzed by 
qRT-PCR. Zhx2 expression increases with age in both male (A) and female (B) 
offspring until d28. Zhx2 levels continue to increase in male mice from d28 to 
d56. Cyp2a4 expression is positively regulated in males (C) and females (D) until 
d28. Around sexual maturity at d56, male mice have almost complete repression 
of Cyp2a4 while females continue to express it. Developmental expression 
compared to e17.5, *p<0.05, **p<0.01, ***p<0.001.  
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Figure 14. Zhx2 regulation of female-specific Cyps. Eight Cyp genes 
characterized as being more abundant in females were analyzed. Liver mRNA 
was analyzed by qRT-PCR in Zhx2f/f and Zhx2∆hep littermates. Although not 
statistically significant, expression trends are apparent. Two genes, Cyp2b13 (C) 
and Cyp2b9 (G) increased dramatically in male Zhx2∆hep mice. Cyp4a10 (A), 
Cyp3a16 (B), Cyp39a (D) and Cyp2c40 (E) increased modestly in male Zhx2∆hep 
mice. Cyp1a1 (F) and Cyp1a2 (H) did not differ with Zhx2 status. Cyp1a2 (H) 
was lower in female Zhx2∆hep mice; hepatic Zhx2 expression did not affect 
expression of other female biased CYPs. *p<0.05. 
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Figure 15. Zhx2 regulation of male-specific Cyps. Three Cyp genes typically 
more abundant in males were analyzed by qRT-PCR. There is no difference in 
expression in male Zhx2∆hep mice from controls. Female Zhx2∆hep mice had lower 
expression of Cyp4a12 (B) and Cyp8b1 (C). *p<0.05 , ****p<0.0001.  
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Figure 16. Zhx2 regulation of gender-neutral Cyps. Analysis by qRT-PCR of 
Cyp genes expressed equally in males and females indicated hepatic Zhx2 does 
not alter their expression in males. Cyp7a1 (C) was reduced in female Zhx2∆hep 
mice. *p<0.05.  
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Figure 17. Cyp2a4 is disregulated in HCC. B6C3F1 male mice were injected 
with DEN (n=15) or PBS (n=5) to induce HCC tumor formation. Samples were 
collected 36 weeks post-injection. Tumor samples had 40-fold higher Cyp2a4 
than control liver. ****p<0.0001.  
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Figure 18. Zhx2 involvement in Growth hormone-STAT5 signaling to 
regulate gender-specific CYP expression. Female mice have continuous 
growth hormone (GH) signaling that activates STAT5a and STAT5b 
heterodimers to promote female-specific CYP expression. Male mice have GH 
pulses that activate STAT5b homodimers, possibly coordinated with HNF4α, to 
activate male-specific CYP genes and cause repression of female-specific CYPs. 
Our data suggest Zhx2 may be the male-specific repressor of female CYPs, 
explaining the elevated female-specific CYP expression in exhibited in male 
Zhx2∆hep mouse livers.   
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Chapter 5 
Zhx2 regulates hepatic Elovl3, a fatty acid elongase with tumor suppressor 
qualities  
Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer 
globally, and is the third leading cause of cancer deaths [129]. The prevalence of 
HCC in the United States is relatively low compared to other cancers and is 
primarily attributed to alcoholic liver disease and infection with Hepatitis C Virus 
(HCV) and, to a lesser extent, with Hepatitis B Virus (HBV) [130]. In the past 
several decades, there has been a surge in both cases and deaths from HCC in 
the U.S., and a large portion are correlated with the increasing rates of obesity 
and Type 2 Diabetes [15, 131]  With the expected increase of obesity and 
associated clinical manifestations, the incidence of HCC is expected to increase 
and be the third leading cause of cancer deaths in the United States by 2030 
[24]. The high death rate resulting from HCC is due in part to a lack of early 
detection methods and poor understanding of early events in the progression of 
the disease. Currently, the most commonly used detection method for liver 
damage is serum screening for elevated alpha-fetoprotein (AFP). AFP has been 
used as a diagnostic marker for liver damage and possible HCC for over 40 
years [132]. AFP is expressed abundantly in the fetal liver, dramatically 
repressed at birth, and reactivated in liver damage and liver cancer, and thus 
was the first identified and well-characterized HCC oncofetal protein.  
In contrast to other mouse strains, AFP continues to be expressed in the 
adult liver of BALB/cJ mice. This recessive trait has provided the basis for studies 
on postnatal AFP regulation and enabled us to identify the genetic basis for 
persistent AFP expression [26]. By positional cloning, we found that the loss of 
postnatal AFP repression was due to a hypomorphic mutation in the BALB/cJ 
Zinc fingers and homeoboxes 2 (Zhx2) gene [31, 81]. Several other genes that 
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are expressed abundantly in the fetal liver and repressed at birth, including H19, 
Glypican 3 (Gpc3), and Lipoprotein lipase (Lpl, unpublished), are also expressed 
in BALB/cJ adult liver; these genes are also targets of Zhx2 [29, 81]. 
Interestingly, all of these targets are also frequently reactivated in HCC. While 
AFP and Gpc3 are used clinically as diagnostic markers, a functional role for 
these proteins in HCC cause or progression has not been demonstrated. Due to 
the fact that AFP, H19 and Gpc3 are reactivated in HCC, there is interest in 
identifying other Zhx2 targets that might contribute to HCC progression and/or 
serve as biomarkers of liver disease. 
Microarray data provided by our collaborator, Jake Lusis (University of 
California, Los Angeles) identified Elongation of very long chain fatty acids-like 
3 (Elovl3) as a potential Zhx2 target. Elovl3 is a member of a family of seven 
mammalian fatty acid elongases (Elovl1-7) that are required for de novo 
synthesis of very long chain fatty acids (VLCFAs) up to 24 carbons in chain 
length [84]. Each elongase in this family has distinct tissue distribution and 
substrate specificity, making them important regulators of cellular lipid 
composition as well as specific cellular functions [133]. The Elovl3 enzyme 
synthesizes C20-C24 saturated and monounsaturated fatty acids and is most 
abundantly expressed in skin sebaceous glands, brown and white adipose, and 
the liver [133]. Prior reports indicate Elovl3 in the skin is imperative for proper 
barrier function [134] and is important in brown fat for activation of thermogenesis 
in response to cold exposure [135]. However, the role of Elolv3 in the liver has 
not been investigated. Here, using several mouse models, we tested whether 
Elovl3 is a target of Zhx2. Our data indicate that Elovl3 is controlled by Zhx2. In 
contrast to other Zhx2 targets that are silenced in the postnatal liver and 
repressed by Zhx2, hepatic Elovl3 mRNA levels increase after birth and are 
positively regulated by Zhx2. This led us analyze Elovl3 mRNA levels in 
regenerating liver and in HCC. We find that Elovl3 levels decrease in a mouse 
models of liver regeneration and in mouse liver tumors. Based on these data, we 
investigated whether the loss of Elovl3 has a causal role in HCC progression. We 
have found that forced Elovl3 expression reduces growth of human hepatoma 
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cells in soft agar. Consistent with this, flow cytometry indicates that Elovl3 alters 
cell cycle progression and expression of cyclins. Studies by our collaborators in 
China indicate that Elovl3 mRNA levels are significantly decreased in human 
HCC samples compared to adjacent non-tumor regions. Taken together, this 
data indicates that Elovl3 might function as a tumor suppressor in HCC and is a 
novel biomarker of HCC in humans.  
Results 
Hepatic Elovl3 mRNA levels are reduced in the absence of Zhx2. 
Microarray data suggested that Elovl3 might be a target of Zhx2. However, 
in contrast to previous Zhx2 targets that are higher when Zhx2 levels are 
reduced, Elovl3 levels appear to be decreased when Zhx2 levels are lower. This 
suggests that Elovl3 is positively regulated by Zhx2. To explore this further, 
studies were carried out in mice in which the Zhx2 gene was deleted in 
hepatocytes (Zhx2∆hep) mice and littermate controls (Zhx2f/f) (described in 
Chapters 2 and 3). To confirm the reduction in Zhx2 levels, qPCR was performed 
with cDNA from Zhx2∆hep and control Zhx2fl/fl mice (Figure 19). Zhx2 mRNA levels 
in 5 week old Zhx2∆hep mice were roughly 3% the levels seen in Zhx2f/f 
littermates, consistent with deletion of the Zhx2 gene in hepatocytes (Figure 
19A). The remaining Zhx2 expression in Zhx2∆hep liver is likely due to Zhx2 
expression in non-parenchymal cells where Alb-Cre is not active. Elovl3 mRNA 
levels were also significantly reduced in Zhx2∆hep livers (Figure 19B), indicating 
that Elovl3 is the first gene positively regulated by Zhx2.   
Elovl3 is developmentally activated in the perinatal mouse liver. 
Previously identified Zhx2 targets, including AFP, H19 and Gpc3, are 
silenced in the liver after birth and repressed by ZHx2. In contrast to these 
genes, Elovl3 appears to be positively regulated by Zhx2. This suggests that 
Elovl3 might be developmentally activated during the perinatal period. To test 
this, livers were removed from C3B6F1 mice at e17.5 and postnatal day 1 (p1), 
p7, p14, p21, p28 and p56. Since Elovl3 is expressed at higher levels in adult 
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male mice than in female mice, studies were performed in both sexes. RNA was 
extracted and analyzed by RT-qPCR for Zhx2 and Elovl3. Hepatic Zhx2 mRNA 
expression is very low but detectable at e17.5 and gradually increased in both 
male and female livers until p28 (Figure 20A, B). However, Zhx2 levels remain 
relatively constant in female mice for the next four weeks, but increased roughly 
6-fold in male mice between p28 and p56, suggesting that this male-specific 
Zhx2 increase between four and eight weeks coincides with sexual maturity. 
Elovl3 in male liver also showed a gradual but modest increase between e17.5 
and p28 (Figure 20C). In female livers, Elovl3 levels remain relative constant until 
p21 but increased somewhat by p28 (Figure 20D). Interestingly, at p28, Elovl3 
mRNA levels are 10-fold higher in female than in males. However, between p28 
and p56, hepatic Elovl3 levels increase ~10-fold in males and decrease ~20-fold 
in females. The dramatic rise in Elovl3 in male mice between p28 and p56 
coincides with the increase in Zhx2, whereas Elovl3 levels decrease in females 
during this period even though Zhx2 levels stay relatively constant. This data 
indicates that male-biased Elovl3 expression is established between 1 and 2 
months of age.  
Zhx2 regulation of elongase family members in adult liver. 
The seven mammalian elongases (Elovl1-7) are similar in sequence and 
structure, and there is some overlap and redundancy in their enzymatic activities 
[84, 133]. Due to the strong impact Zhx2 expression has on Elovl3, we examined 
whether expression of the other elongases at four weeks of age changed in the 
absence of Zhx2. Elovl1 mRNA levels were significantly lower in Zhx2∆hep liver. 
Elovl5 and Elovl6 showed this same trend but the difference between Zhx2∆hep 
and Zhx2f/f livers did not reach significance. Elovl2 showed no change of 
expression. Elovl4 and Elovl7 are not normally expressed in the liver and were 
not detected in these samples (Figure 21 and data not shown).  
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Elovl3 is repressed in the regenerating liver, and controlled by Afr2. 
Hepatocytes are normally quiescent in the adult liver, but have the ability 
to re-enter the cell cycle after injury to restore the liver to its original size and 
function [136]. This regenerative capacity is of great importance since a number 
of drugs and environmental chemicals are toxic to hepatocytes. Carbon 
tetrachloride (CCl4) is a well-studied hepatotoxin that induces liver regeneration. 
In adult mice, an intraperitoneal injection of 5 ul of CCl4 will kill roughly 70% of 
hepatocytes, and over a 5-7 day period after this insult the liver will regenerate to 
its normal size. All known targets of Zhx2, including AFP, are silent in the healthy 
adult liver but are transiently reactivated during liver regeneration, with peak 
expression occurring ~3 days after injury. Reactivation of these Zhx2 targets is 
lower in BL/6 mice than in other mouse strains. This low AFP induction in BL/6 
mice is a dominant trait governed by a single locus on mouse Chromosome 2 
called Alpha-fetoprotein regulator 2 (Afr2). Since every known target of Zhx2 is 
regulated by Afr2, we tested whether Elovl3 mRNA levels changed in 
regenerating liver and also be regulated by Afr2. Liver regeneration was initiated 
in C3H and BL/6 mice by a single IP injection of CCl4 in mineral oil, or mineral oil 
alone as control. Mice were killed and livers removed 72 hours post-injection. As 
expected, AFP levels were low in both strains when treated with mineral oil, 
whereas the AFP induction was much higher in C3H mice than in BL/6 mice 
(Spear lab, unpublished). Elovl3 levels were about the same in both strains 
treated with mineral oil. After CCl4 treatment, Elovl3 mRNA levels were reduced 
but the extent of reduction was greater in C3H than in BL/6 mice. Since Elovl3 
regulation by Zhx2 is opposite what is seen with AFP, It is not surprising that 
Elovl3 levels decreased, rather than increased, in regenerating liver. The more 
robust repression of Elovl3 in C3H compared to BL/6 liver indicates that Elovl3 is 
also regulated by Afr2 during liver regeneration.  
Elovl3 is repressed in a mouse model of HCC. 
While the liver regeneration in response to a single insult is a short-term 
proliferative response, persistent damage and/or treatment with mutagenic 
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agents can lead to tumor formation [137]. AFP and all other Zhx2 targets are 
classified as oncofetal genes in that they are expressed in fetal tissues, 
developmentally silenced at birth, and reactivated in cancer, including 
hepatocellular carcinoma (HCC). The dramatic reduction in Elovl3 during liver 
regeneration led us to ask if Elovl3 is also repressed in HCC. Male B6C3F1 mice 
were treated with the tumor initiator DEN. After 36 weeks, mice were killed. 
Those receiving no DEN had no tumors, whereas all DEN-treated mice had 
multiple tumors. qRT-PCR analysis showed an almost complete repression of 
Elovl3 expression in tumors (Figure 22A). Other elongase family members also 
exhibited altered expression in tumors (Figure 22B), but not to the same extent 
as Elovl3. Elovl2 expression increased over two-fold in tumor samples, whereas 
Elovl6 expression was decreased roughly 60%.  
Elovl3 expression reduces anchorage-independent cell growth and stalls cell 
cycle progression in S phase. 
Loss of Elovl3 mRNA and protein expression during liver regeneration and 
in HCC tumors led us to consider whether Elovl3 may influence cell proliferation. 
Anchorage independent cell growth is a noted feature of transformed cells, which 
can be measured by growth in soft agar. We examined the effect of Elovl3 
expression in Huh7 cells, a human HCC cell line that has negligible endogenous 
Elovl3 expression. Cells transfected with expression plasmids for either Elovl3 or 
pcDNA3.1 empty vector were seeded at 5000 cells per well in media-
supplemented soft agar, cultured for one week, and measured by a luminescent 
viability assay. Elovl3 transfected cells exhibit 35% reduced growth compared to 
pcDNA3.1-transfected control cells (Figure 23). A similar (~30%) reduction in cell 
growth was seen in Elovl3-transfected Huh7 cells grown as monolayers (data not 
shown).   
This data led us to look more closely at Elovl3 and cell cycle progression. 
Hela cells were transfected with a GFP expression plasmid along with Elovl3 
expression vector or control pcDNA3.1 and synchronized. Cells were then 
analyzed by flow cytometry at various times after release from the double-
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thymidine block. Propidium iodide (P.I.) staining of GFP-positive cells indicated 
that as early as one hour after release, Elovl3 expression results in fewer cells in 
G2 and an increased proportion of cells in S phase when compared to 
pcDNA3.1-transfected cells (Figure 24). This trend continued to hold for the first 
8 hours after release; control cells begin to progress to G2 roughly three hours 
after release whereas Elovl3 cells do not show noticeable G2 progression until 5 
hours, suggesting that Elovl3 stalls cells in the S phase.  
The cell cycle is a tightly regulated process that requires the coordinated 
expression of several cyclins at varying points in the cycle, as well as the 
association of the appropriate cyclin-dependent kinase (CDKs) [138]. Previous 
studies have shown that Zhx2 regulates the expression of cyclins E and A [35], 
which are necessary for the proper progression of cells from G1 to S-phase and 
S-phase to G2, respectively. As Zhx2 regulates Elovl3 and our data indicate that 
Elovl3 reduces cell proliferation and alters the cell cycle, we next examined the 
effect of Elovl3 on cyclin expression at the hourly timepoints after cell 
synchronization. Cyclins D, E, A, and B mRNA levels are similar in Elovl3-
transfected and pcDNA3.1-transfected control cells until hour 3 (Figure 25). At 
this time, control cells show a surge in expression of Cyclins D, E, and A, and a 
modest increase in Cyclin B. The increased cyclin expression coincides with the 
increased number of cells progressing to G2 at this timepoint. In contrast, the 
surge in Cyclins E, A and B in Elovl3-transfected cells is delayed until hour 5. 
Elovl3-transfected cells do not exhibit a surge in Cyclin D that is seen in control 
cells.  
Discussion 
Identification of Zhx2 was based on the continued expression of AFP and 
other fetal genes in the adult liver of BALB/cJ mice. This and additional studies 
indicate that Zhx2 is a repressor of AFP and other target genes that are silenced 
at birth. Data shown in this chapter indicate that Elovl3 is also a target of Zhx2. In 
contrast to other targets, Elovl3 is the first gene that appears to be positively 
regulated by Zhx2. Our data show that Elovl3 levels are significantly reduced in 
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Zhx2∆hep mice compared to Zhx2f/f control littermates (Figure 19). Consistent with 
this data, Elovl3 levels are higher in BALB/cJ mice that express a liver-specific 
Zhx2 transgene than in non-transgenic BALB/cJ littermate controls (Spear lab, 
unpublished). In addition, Elovl3 mRNA levels increase during the first four 
weeks after birth, a time when Zhx2 mRNA levels are also increasing (Figure 20). 
In vitro studies by our collaborators in China indicate that endogenous Elovl3 
mRNA levels in human hepatoma cell lines increase in Zhx2-transfected cells, 
whereas these Elovl3 levels decrease when Zhx2 levels are reduced by miRNA 
knock-down (Ma et al, unpublished). While these studies indicate that Elovl3 is 
positively regulated by Zhx2, they do not distinguish whether this regulation is 
direct or indirect. Further studies, including ChIP, will be needed to distinguish 
between these possibilities and to identify the cis-acting site(s) in the Elovl3 
regulatory region required for Zhx2 responsiveness. It should also be noted that 
nuclear run-on studies performed in Dr. Peterson’s lab indicate that Zhx2 might 
act, at least in part, at the post-transcriptional level. Thus, further studies will be 
needed to fully understand the mechanism by which Zhx2 regulates target gene 
expression. 
It is of great interest that Elovl3 is the first positively regulated Zhx2 target 
and is expressed in normal adult mouse livers. The increasing levels of Zhx2 and 
Elovl3 in the perinatal period matches the physiological need for proper skin and 
fur development [134], thermal regulation [135], and maintenance of storage 
triglyceride pools [133].  While our studies have focused on liver, future studies 
should evaluate Zhx2 and Elovl3 in other tissues, particularly skin and brown 
adipose tissue.   
Previous mouse studies have shown that Elovl3 is expressed at higher 
levels in males than in females [122]. The transcriptional basis for this gender-
biased expression is not fully understood. We found that Elovl3 levels increase in 
both sexes in the first month after birth, but were puzzled to find that Elovl3 
mRNA levels were roughly 10-fold higher in female liver than in male liver at p28. 
However, we observed a dramatic increase and decrease of Elovl3 in male and 
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female liver, respectively, between p28 and p56, resulting in male-biased 
expression by 2 months of age that is consistent with other reports. Since this 
Elovl3 increase in males coincides with a dramatic increase in Zhx2 levels and 
occurs at a time of sexual maturity, it is possible that male hepatic Elovl3 
expression is regulated by growth hormone signaling. Whether Zhx2 is also 
regulated by growth hormone will require further study. It should also be noted 
that Elovl3 displays a circadian expression pattern in males, whereas female 
mice appear to have constant, low-level Elovl3 expression [122, 139]. Zhx2 also 
exhibits a circadian pattern of expression (K. Esser, Personal communication), 
suggesting a possible role for Zhx2 in diurnal changes in the expression of Elovl3 
and other target genes.   
While Elovl3 levels are low in adult female mice, this basal Elovl3 
expression is still sufficient to have physiological impact. Zadravec et al. [86] 
reported that Elovl3 ablation resulted in resistance to diet-induced obesity and 
was much more pronounced in females than males. The sex difference in the 
magnitude of expression is similar in the other elongase family members as well. 
Although the potential impact is unknown, it would be interesting to determine if 
the constant elongase expression in females result in a favorable lipid pool 
concentration that confers protective effects and reduces disease risks in women 
more so than men. 
Previously identified Zhx2 targets are disregulated in HCC. Most, but not 
all studies suggest that AFP and H19 do not have functional role in HCC 
progression, but there is strong data that Gpc3 can promote cancer [46, 47]. This 
raises the question whether Zhx2 regulates liver tumor formation.  Data from Dr. 
Chunhong Ma and colleagues at Shandong University in China, with whom we 
have had a longstanding collaboration, suggest that Zhx2 proteins are primarily 
in the nucleus in normal hepatocytes but are localized in the cytoplasm in HCC 
samples. This would suggest that Zhx2 is disregulated in HCC, and that this is 
occurring at the post-translational level.  Irrespective of Zhx2, we have found that 
Elovl3 is repressed in mouse HCC samples. Preliminary analysis of human 
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samples at Shandong University show no significant differences in Elovl3 mRNA 
levels between human HCC samples and surrounding non-tumor tissues, but 
further analysis is warranted.   
The dramatic downregulation of Elovl3 in liver regeneration and HCC 
samples in mice led us to investigate a causal role for Elovl3 in cell proliferation. 
By transfections in cultured cells, our data indicate that Elovl3 can repress Huh7 
growth in soft agar and in cell monolayers and can alter Hela cell cycle 
progression and Cyclin expression. A functional consequence of reduced Elovl3 
levels could include a diminished supply of saturated and monounsaturated 
VLCFAs that would disrupt cell membrane integrity and fluidity, and the synthesis 
of sphingolipids [140].  Elovl3 expression in the liver is necessary for the 
generation of C20:1, C22:1, and C24:1 VLCFAs. Lipids of these categories are 
generally incorporated into sphingolipids in the plasma membrane and have 
been implicated in roles of signaling events, proliferation, and apoptosis [141, 
142].  Future studies should explore the relationship between Elovl3 and these 
lipids and how this might influence cell proliferation. 
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Figure 19. Zhx2 positively regulates Elovl3 expression in adult mouse liver. 
Liver RNA from male Zhx2f/f and Zhx2∆hep littermates analyzed by qRT-PCR. 
Zhx2 deletion from hepatocytes (A) results in reduction of Elovl3 expression 
nearly 75% (B). *p<0.05, ***p<0.001.  
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Figure 20. Elovl3 is developmentally activated in the perinatal mouse liver, 
but silenced in female adult liver. Liver RNA extracted from B6C3F1 offspring 
collected at developmental timepoints was analyzed by qPCR. Zhx2 expression 
increases with age  (A, B) and Zhx2 increases with sexual maturation in male 
mice by d56. Correspondingly, Elovl3 expression increases during development  
(C, D). At d56, female mice have ~20-fold Elovl3 repression while males have 
~10-fold increase. Developmental expression compared to e17.5, *p<0.05, 
**p<0.01, ***p<0.01.  
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Figure 21. Expression of elongase genes in male liver. Liver RNA from 5-
week old Zhx2f/f and Zhx2∆hep littermates was analyzed by qRT-PCR for relative 
elongase expression. Elovl3 and Elovl2 are the most abundantly expressed 
elongases in the liver. Elovl1 has low hepatic expression and is reduced in 
Zhx2∆hep mice, as is Elovl3 expression. *p<0.05.  
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Figure 22. Elovl3 is repressed in a mouse model of HCC. B6C3F1 male mice 
were injected with DEN (n=15) or PBS (n=5) to induce HCC tumor formation. 
Samples were collected 36 weeks post-injection. Elovl3 expression was 
dramatically reduced in tumors (A). Other elongases are also disregulated in 
HCC (B); Elovl2 is activated and Elovl6 is repressed. *p<0.05, ****p<0.001. 
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Figure 23. Elovl3 suppresses HCC cell  anchorage independent growth. 
Huh7 cells were transfected with either pcDNA3.1 empty vector (control) or 
Elovl3 expression plasmid, plated in media-supplemented soft agar and 
incubated for one week. Cell viability was measured using a luminescent DNA 
binding dye. Controls were set to 100%. Elovl3 expression reduced cell growth 
by 30%. *p<0.05. 
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Figure 24. Elovl3 expression stalls cell in S-phase. Hela cells were co-
transfected with GFP and either pcDNA3.1 empty vector (Control) or Elovl3 
expression plasmid. Cells were synchronized in G1 then collected at hourly 
timepoints after release. GFP positive cells were analyzed by FACS to determine 
the proportion of cells in each cell cycle phase. Elovl3 and control cells are not 
different in progression through G1 (A). Elovl3 expression increases the number 
of cells in S-phase (B) which accounts for fewer cells in G2/Mitosis (C).  This 
data suggests that Elovl3 reduces cell proliferation by stalling cells in S-phase.  
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Figure 25. Elovl3 expression alters expression of Cyclins. Cell RNA was 
collected at hourly timepoints after release from G1 synchronization and 
analyzed by qRT-PCR for expression of Cyclin D, E, A, and B. Control cells 
increase expression of Cyclins D, E, and A three hours after release (A, B, C). 
Expression of Cyclins is delayed and blunted in Elovl3 transfected cells.  Altered 
expression of Cyclins could contribute to the delay of cell progression through the 
cell cycle.  
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Chapter Six 
Summary and Future Directions 
The data reported in this dissertation characterize Zhx2 as a 
transcriptional regulator of genes involved in lipid, steroid and xenobiotic 
metabolism, sex-specific gene patterning, and cell cycle regulation. Zhx2 has 
previously been reported to act directly on some of its targets to repress 
expression (AFP, Cyclins A and E, Gpc3)  [34, 35, 143]. To date, the mechanism 
by which Zhx2 regulates many of its targets has not been determined. The fact 
that some targets are positively regulated while others are expressed suggests 
Zhx2 may part of a much larger signaling and regulatory complex. 
This dissertation describes the first analysis using mice with a floxed Zhx2 
allele.  My studies in Zhx2∆hep mice have identified new Zhx2 targets in entirely 
new areas of metabolism and cell function. Based on findings in studies with 
BALB/cJ mice, we expected that Zhx2 regulated many genes in lipid and 
cholesterol metabolism. I found that Zhx2 regulates ChREBP, Cpt1a, MAT1a, 
and CD36. The functional parameters of these genes align with characteristics of 
previously identified targets. Interestingly, Zhx2 appears to impact levels of 
transcription factors HNF4α and PPARγ. HNF4α, in particular, is a major 
regulator of liver gene expression. HNF4α is critical to liver function; deletion of 
the gene is embryonic lethal [96, 144] and loss of expression increases cell 
proliferation and HCC [145]. My finding that Zhx2 deletion in hepatocytes 
reduces HNF4α expression implicates Zhx2 involvement, at least by indirect 
means, of a large portion of genes and metabolic functions in the liver. To gain 
better insight into the function and impact of Zhx2, ChIP-seq analysis should be 
performed to identify targets with which Zhx2 has direct interaction, and RNA-seq 
data will provide a better understanding of the broader effects of Zhx2 on gene 
expression. Multiple HNF4α binding sites have been found in the Zhx2 promoter 
(K. Schroeder, personal communications), suggesting potential cross-talk 
between these factors that govern similar hepatic functions.   
77 
 
 
Another interesting facet of Zhx2 is its role in developmental gene 
expression. Zhx2 targets that we have investigated in detail in mouse 
development (AFP, Cyp2a4, Elovl3) display an expression pattern from 
embryonic to young adulthood that corresponds with increasing Zhx2 levels 
during this timeframe. This development regulation has become a hallmark of 
Zhx2 targets. In addition to HNF4α, the Zhx2 targets Lpl, Gpc3, and Cpt1a are 
necessary for proper fetal development and mutations in these genes can cause 
perinatal death. Since Zhx2∆hep mice could be obtained, liver-specific Zhx2 
expression is not absolutely essential. However, while not included in this 
dissertation, breeding Zhx2∆hep mice revealed an extremely unusual phenotype in 
that some offspring were born underdeveloped and missing internal organs, and 
many others dies within 24 hours of birth. Perinatal death in Zhx2∆hep mice could 
be the consequence of its disregulated targets that are important for metabolism. 
The early developmental abnormalities (absence of posterior half of embryos, 
lack of internal organs) seen in some of the offspring are quite puzzling, and the 
physical deformities were more severe than what has been characterized in other 
gene deletions. These defects are not due to the lack of Zhx2 in the livers of 
offspring, but are a consequence of the lack of hepatic Zhx2 in the mothers. 
While we do not know the molecular basis for this phenomenon, it is possible that 
the maternal hepatic Zhx2 deletion alters nutrient availability and/or ineffective 
signaling molecules essential for early embryonic patterning. This raises the 
question of whether maternal Zhx2 expression and proper regulation of Zhx2 
targets is required for proper fetal development in humans. Additional research 
into this topic is needed.  
My results identifying Zhx2 as a regulator of Cyp2a4 during sexual 
maturity of male mice reveals a new role for Zhx2. The dramatic increase in Zhx2 
expression seen only in male mice from 4 weeks of age to 8 weeks of age 
suggests Zhx2 is activated by steroid hormone signaling during sexual 
maturation. Increased Zhx2 in sexually mature male mice could increase 
expression of STAT5b and HNF4α, as my data indicates they are both positively 
regulated by Zhx2 expression in 5 week old mice, but this needs to be further  
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examined in older mice. My data provides compelling evidence that Zhx2 is an 
important component of the GH-STAT5-HNF4α signaling axis that is necessary 
for sex-specific gene expression in the liver. The difference in the expression of 
multiple Cyp enzymes in males and females has great implications in disease 
risks. In mice and in humans, males are generally at higher risk than women for 
fatty liver, liver damage, and HCC . In contrast, women are at higher risk of liver 
damage from alcohol use [146]; incidentally, women may have lower expression 
of Cyp2e1, the enzyme that metabolizes alcohol [147, 148]. CVD is the primary 
cause of death for both men and women in America, but the characteristics differ 
between sexes. CVD onset is delayed in women with complications appearing 
about 10 years later than the average age of men [149]. Menopause and 
hormonal perturbations coincide with the timing of CVD presentation in women. 
Since GWAS studies have confirmed Zhx2 as a risk factor for CVD in humans 
[76, 77], it is tempting to speculate that Zhx2 may contribute to the gender 
differences in disease susceptibility through its coordination of hormone signaling 
and sex-specific gene patterning. Differential Cyp gene expression could 
contribute to altered steroid and xenobiotic metabolism and directly impact the 
development of both fatty liver and cardiovascular disease, as well as the 
efficacy of therapeutic interventions for these conditions. Therefore, the 
cardioprotective phenotype seen in BALB/cJ mice might be due in part to the 
“feminization” of the liver caused by diminished Zhx2 and altered sex-specific 
expression of Cyps and other proteins. An extension of this observation would be 
to see if hepatic Zhx2 deletion causes a switch in gender-associated disease, i.e. 
if female Zhx2∆hep mice have increased liver damage and HCC compared to 
males. Further, I have established a role for Zhx2 in the sexual maturity of male 
mice, and our lab has shown its role in gene regulation during development. As 
sex hormones diminish with age, it is logical to examine the expression of Zhx2 
in aging mice as well. It will be interesting to explore the role of sex hormones on 
Zhx2 expression, hepatic gene regulation, and the resulting risk of both liver 
damage and cardiovascular disease throughout the life cycle in mice.  
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Zhx2 regulation of Elovl3 provides novel insight into the role of Zhx2 in 
lipid signaling and cellular metabolism. AFP and H19 are known to be 
disregulated in HCC and are clinically relevant as biomarkers, but it is not clear if 
or how their increased expression is involved in tumor formation. Gpc3, another 
Zhx2 target, is a cell surface proteoglycan that has been shown to influence liver 
tumor formation [150].  However, my data showing a link between Zhx2, Elovl3, 
and cell proliferation represents metabolism as another means by which Zhx2 
might influence HCC. Elovl3 synthesizes VLCFAs which often are incorporated 
into cell membranes, constitute sphingolipids, and are conductors of signaling 
events.[141, 142] There is growing interest in the role of sphingolipids, and 
ceramide metabolites, in regulating important cell fate processes such as growth 
and proliferation, apoptosis, and autophagy, among others. Ceramides and their 
analogues are being tested as therapeutics for cancers due to their role in cell 
cycle arrest and inducing apoptosis [151, 152]. My data shows that Elovl3 
expression contributes to cell cycle arrest, but the mechanism is unknown. It is 
possible that treatment of cancerous cell lines with Elovl3 lipid products could 
recapitulate the results of my study. Work is being done in our lab to isolate, 
culture and transfect primary hepatocytes, which will be an ideal model to 
perform these studies. Transfections with Elovl3 expression plasmids in these 
cells followed by LCMS analysis could identify the ceramide or sphingolipid 
compounds resulting from Elovl3 activity under normal condition. These lipids or 
synthetic analogs could be used to treat cells exposed to carcinogenic toxins to 
evaluate the effectiveness in regulating cell proliferation in a disease model. 
Further understanding of the role of Elovl3 in cell cycle regulation could provide a 
new avenue for therapeutic potential.  
Zhx2 regulates genes involved diverse functions that are important for 
health and normal metabolism. This makes Zhx2 a potential target for 
manipulation and mutation in disease. Many of the processes that are 
disregulated in Zhx2∆hep mice parallel activities attributed to the mTOR pathway. 
mTOR complex 1 (mTORC1) receives signals from insulin and growth factors 
and senses nutrient status through AMP/ATP ratio and amino acid abundance 
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[153]. mTORC1 activation results in new gene transcription, increased de novo 
lipogenesis, increased cell growth and proliferation, and inhibition of autophagy. 
mTOR is regulated by feedback inhibition from diminished nutrient availability 
(AMPK), amino acid deprivation, and glucocorticoid signals. When disregulated, 
mTOR activity proceeds without inhibition and can lead to diseases, including 
cardiovascular disease and cancer [153, 154]. Zhx2 is integral in conducting 
signals from GH and effecting gene expression regulation in response. My data 
suggests that disregulated Zhx2 function disengages nutrient sensing of lipids in 
hepatocytes resulting in excess fat accumulation, a condition that is exacerbated 
by faulty lipid export. In HFD conditions, the fatty liver environment in Zhx2∆hep 
mice provides abundant lipid substrate required by cancer cells for membranes 
and signaling molecule in rapidly dividing cells [155]. The apparent overlap of 
mTOR activity and Zhx2 regulation of lipid synthesis, growth signaling, cell 
proliferation, and associations with CVD, cancer, and multiple other disorders 
suggests Zhx2 could be a part of or affected by mTOR pathways. Future studies 
into a relationship between mTOR and Zhx2 disregulation in lipid metabolism and 
cell growth could provide new insight into key events in early stages of CVD and 
liver disease, including HCC.  
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